pmid,nct_id,pub_source,ArticleType,Substance,MeSH,Title,PubDate,Journal,pubmed_links,ctg_links
32251729,NCT04326790,Abstract,Clinical Trial Protocol|Journal Article,Antirheumatic Agents|Troponin|Colchicine|NA,"Antirheumatic Agents|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Colchicine|Coronavirus Infections|Heart Diseases|Humans|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Symptom Assessment|Troponin|NA",The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design.,2020-07-24,Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,https://pubmed.ncbi.nlm.nih.gov/32251729,https://clinicaltrials.gov/ct2/show/NCT04326790
32304640,NCT04315948,Abstract,Journal Article,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Drug Repositioning|Evidence-Based Medicine|Health Services Needs and Demand|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.,2020-06-29,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32304640,https://clinicaltrials.gov/ct2/show/NCT04315948
32330277,NCT04323527,Abstract,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anti-Bacterial Agents|Antiviral Agents|Oseltamivir|chloroquine diphosphate|Azithromycin|Chloroquine|NA,"Adult|Aged|Anti-Bacterial Agents|Antiviral Agents|Azithromycin|Betacoronavirus|Brazil|COVID-19|Chloroquine|Coronavirus Infections|Disease Outbreaks|Dose-Response Relationship, Drug|Double-Blind Method|Female|Humans|Male|Middle Aged|Oseltamivir|Pandemics|Pneumonia, Viral|SARS-CoV-2|Tertiary Care Centers|NA",Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.,2020-04-29,JAMA network open,https://pubmed.ncbi.nlm.nih.gov/32330277,https://clinicaltrials.gov/ct2/show/NCT04323527
32356926,NCT04355936,Abstract,Journal Article,"Angiotensin II Type 1 Receptor Blockers|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|ACE2 protein, human|Angiotensin-Converting Enzyme 2|Telmisartan|NA","Angiotensin II Type 1 Receptor Blockers|Angiotensin-Converting Enzyme 2|COVID-19|Clinical Trials, Phase II as Topic|Humans|Lung|Pandemics|Protein Binding|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Telmisartan|Virus Internalization|NA",Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.,2020-12-04,Drug development research,https://pubmed.ncbi.nlm.nih.gov/32356926,https://clinicaltrials.gov/ct2/show/NCT04355936
32383125,NCT04308668,Abstract,Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|SARS-CoV-2|Severity of Illness Index|NA",Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.,2020-08-24,Canadian journal of anaesthesia = Journal canadien d'anesthesie,https://pubmed.ncbi.nlm.nih.gov/32383125,https://clinicaltrials.gov/ct2/show/NCT04308668
32386744,NCT04321278,Abstract,Editorial,Antimalarials|NA,"Antimalarials|Betacoronavirus|COVID-19|Coronavirus Infections|Global Health|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?,2020-07-24,Medicina clinica,https://pubmed.ncbi.nlm.nih.gov/32386744,https://clinicaltrials.gov/ct2/show/NCT04321278
32391667,NCT04261517,Abstract,Journal Article|Randomized Controlled Trial,"RNA, Viral|Hydroxychloroquine|NA","Betacoronavirus|COVID-19|China|Coronavirus Infections|Humans|Hydroxychloroquine|Pandemics|Pilot Projects|Pneumonia, Viral|RNA, Viral|SARS-CoV-2|Treatment Outcome|NA",[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].,2020-05-12,Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,https://pubmed.ncbi.nlm.nih.gov/32391667,https://clinicaltrials.gov/ct2/show/NCT04261517
32401715,NCT04276688,Abstract,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Drug Combinations|lopinavir-ritonavir drug combination|Interferon beta-1b|Lopinavir|Ribavirin|Ritonavir|NA,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Drug Therapy, Combination|Female|Hong Kong|Hospitalization|Humans|Interferon beta-1b|Lopinavir|Male|Middle Aged|Pandemics|Pneumonia, Viral|Ribavirin|Ritonavir|SARS-CoV-2|NA","Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.",2020-06-02,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32401715,https://clinicaltrials.gov/ct2/show/NCT04276688
32407672,NCT04367831,Abstract,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04367831
32407672,NCT04372589,Abstract,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04372589
32407672,NCT04366960,Abstract,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04366960
32407672,NCT04345848,Abstract,Journal Article,"Anticoagulants|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|fibrin fragment D|NA","Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Disseminated Intravascular Coagulation|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Humans|Pandemics|Platelet Count|Pneumonia, Viral|Prothrombin Time|SARS-CoV-2|Thrombosis|NA",Coagulation abnormalities and thrombosis in patients with COVID-19.,2020-06-09,The Lancet. Haematology,https://pubmed.ncbi.nlm.nih.gov/32407672,https://clinicaltrials.gov/ct2/show/NCT04345848
32423584,NCT04257656,Abstract,Journal Article|Multicenter Study|Randomized Controlled Trial,Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|China|Coronavirus Infections|Double-Blind Method|Female|Humans|Infusions, Intravenous|Male|Middle Aged|Negative Results|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA","Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.",2020-05-29,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32423584,https://clinicaltrials.gov/ct2/show/NCT04257656
32425051,NCT04329832,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Anti-Infective Agents|Hydroxychloroquine|Azithromycin|NA,"Adult|Anti-Infective Agents|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Monitoring|Female|Humans|Hydroxychloroquine|Male|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|Utah|NA","Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.",2020-08-13,Annals of the American Thoracic Society,https://pubmed.ncbi.nlm.nih.gov/32425051,https://clinicaltrials.gov/ct2/show/NCT04329832
32445440,NCT04280705,Abstract,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Adult|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Extracorporeal Membrane Oxygenation|Female|Humans|Kaplan-Meier Estimate|Male|Middle Aged|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Time Factors|Young Adult|NA",Remdesivir for the Treatment of Covid-19 - Final Report.,2020-12-01,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04280705
32448345,NCT04257656,Abstract,Clinical Trial Protocol|Journal Article,Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|China|Clinical Trials, Phase III as Topic|Coronavirus Infections|Double-Blind Method|Equivalence Trials as Topic|Female|Humans|Infusions, Intravenous|Male|Multicenter Studies as Topic|Pandemics|Patient Safety|Pneumonia, Viral|Risk Assessment|Risk Factors|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA","Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.",2020-05-27,Trials,https://pubmed.ncbi.nlm.nih.gov/32448345,https://clinicaltrials.gov/ct2/show/NCT04257656
32450106,NCT04313127,Abstract,"Clinical Trial, Phase I|Journal Article","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Vaccines, Synthetic|Viral Vaccines|NA","Adenoviridae|Adolescent|Adult|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|China|Coronavirus Infections|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunity, Cellular|Immunity, Humoral|Injections, Intramuscular|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|T-Lymphocytes|Vaccines, Synthetic|Viral Vaccines|Young Adult|NA","Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.",2020-06-17,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32450106,https://clinicaltrials.gov/ct2/show/NCT04313127
32459919,NCT04292899,Abstract,"Clinical Trial, Phase III|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Adult|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Hospitalization|Humans|Male|Middle Aged|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.,2020-12-01,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32459919,https://clinicaltrials.gov/ct2/show/NCT04292899
32468508,NCT04321421,Abstract,Clinical Trial Protocol|Journal Article|Multicenter Study, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Immunization, Passive|Pandemics|Plasma|Pneumonia, Viral|SARS-CoV-2|NA",Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.,2020-08-28,Internal and emergency medicine,https://pubmed.ncbi.nlm.nih.gov/32468508,https://clinicaltrials.gov/ct2/show/NCT04321421
32492293,NCT04308668,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Hydroxychloroquine|NA,"Adult|Betacoronavirus|COVID-19|Canada|Coronavirus Infections|Double-Blind Method|Female|Humans|Hydroxychloroquine|Inhalation Exposure|Male|Middle Aged|Occupational Exposure|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|SARS-CoV-2|Treatment Failure|United States|NA",A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,2020-08-12,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32492293,https://clinicaltrials.gov/ct2/show/NCT04308668
32492354,NCT04332991,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural",Antimalarials|Hydroxychloroquine|NA,"Adult|Antimalarials|Betacoronavirus|COVID-19|Coronavirus Infections|Dose-Response Relationship, Drug|Hospitalization|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|SARS-CoV-2|Single-Blind Method|Treatment Outcome|NA",Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.,2020-09-21,Annals of the American Thoracic Society,https://pubmed.ncbi.nlm.nih.gov/32492354,https://clinicaltrials.gov/ct2/show/NCT04332991
32493441,NCT04330638,Abstract,Clinical Trial Protocol|Letter,"Anti-Inflammatory Agents|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|IL6 protein, human|IL6R protein, human|Interleukin 1 Receptor Antagonist Protein|Interleukin-1|Interleukin-6|Receptors, Interleukin-6|tocilizumab|siltuximab|NA","Anti-Inflammatory Agents|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Belgium|Betacoronavirus|COVID-19|Clinical Trials, Phase III as Topic|Coronavirus Infections|Drug Therapy, Combination|Host-Pathogen Interactions|Humans|Interleukin 1 Receptor Antagonist Protein|Interleukin-1|Interleukin-6|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Receptors, Interleukin-6|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA",Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.,2020-06-10,Trials,https://pubmed.ncbi.nlm.nih.gov/32493441,https://clinicaltrials.gov/ct2/show/NCT04330638
32493468,NCT04343768,Abstract,Clinical Trial Protocol|Letter,Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Interferon beta-1b|Lopinavir|Hydroxychloroquine|Ritonavir|Interferon beta-1a|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Drug Therapy, Combination|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Interferon beta-1a|Interferon beta-1b|Iran|Lopinavir|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA","Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.",2020-06-10,Trials,https://pubmed.ncbi.nlm.nih.gov/32493468,https://clinicaltrials.gov/ct2/show/NCT04343768
32493478,NCT04328961,Abstract,Clinical Trial Protocol|Letter,Antiviral Agents|Hydroxychloroquine|Ascorbic Acid|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Antiviral Agents|Ascorbic Acid|Betacoronavirus|COVID-19|Contact Tracing|Coronavirus Infections|Drug Administration Schedule|Female|Humans|Hydroxychloroquine|Incidence|Male|Middle Aged|Multicenter Studies as Topic|Occupational Exposure|Occupational Health|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|Randomized Controlled Trials as Topic|Risk Assessment|Risk Factors|SARS-CoV-2|Time Factors|Treatment Outcome|United States|Virus Shedding|Young Adult|NA",Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.,2020-06-10,Trials,https://pubmed.ncbi.nlm.nih.gov/32493478,https://clinicaltrials.gov/ct2/show/NCT04328961
32503602,NCT04328441,Abstract,Clinical Trial Protocol|Letter,BCG Vaccine|NA,"Absenteeism|Adult|Aged|Aged, 80 and over|BCG Vaccine|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Health Personnel|Hospitalization|Humans|Male|Middle Aged|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Vaccination|NA",Two Randomized Controlled Trials of Bacillus Calmette-GuÃ©rin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.,2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32503602,https://clinicaltrials.gov/ct2/show/NCT04328441
32503620,NCT04360980,Abstract,Clinical Trial Protocol|Letter,Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|Ritonavir|Colchicine|NA,"Betacoronavirus|COVID-19|Colchicine|Coronavirus Infections|Double-Blind Method|Drug Combinations|Hospitalization|Humans|Lopinavir|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|NA",Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.,2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32503620,https://clinicaltrials.gov/ct2/show/NCT04360980
32503657,NCT04333589,Abstract,Clinical Trial Protocol|Letter,"Amides|Antiviral Agents|Pyrazines|RNA, Viral|favipiravir|NA","Adolescent|Adult|Aged|Aged, 80 and over|Amides|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Pyrazines|RNA, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|Young Adult|NA","The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.",2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32503657,https://clinicaltrials.gov/ct2/show/NCT04333589
32503662,NCT04316377,Abstract,Clinical Trial Protocol|Letter,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Norway|Pandemics|Pneumonia, Viral|Pragmatic Clinical Trials as Topic|Research Design|SARS-CoV-2|Viral Load|NA",Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.,2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32503662,https://clinicaltrials.gov/ct2/show/NCT04316377
32503663,NCT04326920,Abstract,Clinical Trial Protocol|Letter,Recombinant Proteins|sargramostim|Granulocyte-Macrophage Colony-Stimulating Factor|Oxygen|NA,"Acute Disease|Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|Clinical Trials, Phase IV as Topic|Coronavirus Infections|Female|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Male|Middle Aged|Oxygen|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Recombinant Proteins|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Young Adult|NA",Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.,2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32503663,https://clinicaltrials.gov/ct2/show/NCT04326920
32511534,NCT04306393,Abstract,Preprint, , ,Protocol of a randomized controlled trial testing inhaled Nitric Oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-CoV-2).,2020-09-28,medRxiv : the preprint server for health sciences,https://pubmed.ncbi.nlm.nih.gov/32511534,https://clinicaltrials.gov/ct2/show/NCT04306393
32512291,NCT04335786,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't",Angiotensin II Type 1 Receptor Blockers|Placebos|Valsartan|NA,"Adult|Angiotensin II Type 1 Receptor Blockers|Betacoronavirus|COVID-19|Coronary Care Units|Coronavirus Infections|Double-Blind Method|Drug Administration Schedule|Humans|Inpatients|Multicenter Studies as Topic|Netherlands|Pandemics|Placebos|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Time Factors|Valsartan|NA","Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.",2020-08-26,American heart journal,https://pubmed.ncbi.nlm.nih.gov/32512291,https://clinicaltrials.gov/ct2/show/NCT04335786
32513231,NCT04341493,Abstract,Clinical Trial Protocol|Letter,Thiazoles|Hydroxychloroquine|nitazoxanide|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Humans|Hydroxychloroquine|Pandemics|Pneumonia, Viral|Prognosis|Randomized Controlled Trials as Topic|Respiration, Artificial|Risk Factors|SARS-CoV-2|Single-Blind Method|Thiazoles|NA",Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial.,2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32513231,https://clinicaltrials.gov/ct2/show/NCT04341493
32513299,NCT04334265,Abstract,Clinical Trial Protocol|Letter,"Antiviral Agents|Drugs, Chinese Herbal|anluohuaxian|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drugs, Chinese Herbal|Female|Humans|Lung|Male|Middle Aged|Multicenter Studies as Topic|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|Walking|Young Adult|NA","Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.",2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32513299,https://clinicaltrials.gov/ct2/show/NCT04334265
32513308,NCT04359810,Abstract,Clinical Trial Protocol|Letter,"Antibodies, Viral|NA","Adult|Antibodies, Viral|Betacoronavirus|COVID-19|Clinical Trials, Phase II as Topic|Coronavirus Infections|Humans|Immunization, Passive|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|NA",Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.,2020-06-30,Trials,https://pubmed.ncbi.nlm.nih.gov/32513308,https://clinicaltrials.gov/ct2/show/NCT04359810
32518419,NCT04338958,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Anti-Inflammatory Agents|Cytokines|INCB018424|Protein Kinase Inhibitors|Pyrazoles|JAK1 protein, human|JAK2 protein, human|Janus Kinase 1|Janus Kinase 2|NA","Adult|Aged|Aged, 80 and over|Anti-Inflammatory Agents|Betacoronavirus|COVID-19|Clinical Trials as Topic|Coronavirus Infections|Cytokine Release Syndrome|Cytokines|Drug Administration Schedule|Female|Gene Expression Regulation|Humans|Immunity, Innate|Inflammation|Janus Kinase 1|Janus Kinase 2|Male|Middle Aged|Pandemics|Patient Safety|Pneumonia, Viral|Protein Kinase Inhibitors|Pyrazoles|Retrospective Studies|SARS-CoV-2|Severe Acute Respiratory Syndrome|T-Lymphocytes|Treatment Outcome|NA",The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.,2020-07-14,Leukemia,https://pubmed.ncbi.nlm.nih.gov/32518419,https://clinicaltrials.gov/ct2/show/NCT04338958
32522282,NCT04322396,Abstract,Clinical Trial Protocol|Letter,Antiviral Agents|Hydroxychloroquine|Azithromycin|NA,"Antiviral Agents|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Care|Denmark|Double-Blind Method|Drug Administration Schedule|Hospital Mortality|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Inpatients|Length of Stay|Multicenter Studies as Topic|Noninvasive Ventilation|Pandemics|Patient Admission|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Time Factors|Treatment Outcome|NA",Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.,2020-06-17,Trials,https://pubmed.ncbi.nlm.nih.gov/32522282,https://clinicaltrials.gov/ct2/show/NCT04322396
32532356,NCT04336254,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter", ,"Adolescent|Adult|Aged|Betacoronavirus|COVID-19|Coronavirus Infections|Dental Pulp|Female|Humans|Male|Middle Aged|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Stem Cell Transplantation|Transplantation, Homologous|Young Adult|NA",Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).,2020-06-22,Trials,https://pubmed.ncbi.nlm.nih.gov/32532356,https://clinicaltrials.gov/ct2/show/NCT04336254
32554923,NCT04369469,Abstract,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review", ,"Betacoronavirus|Blood Coagulation|COVID-19|Complement Activation|Coronavirus Infections|Endothelial Cells|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",The complement system in COVID-19: friend and foe?,2020-08-17,JCI insight,https://pubmed.ncbi.nlm.nih.gov/32554923,https://clinicaltrials.gov/ct2/show/NCT04369469
32555385,NCT04354259,Abstract,Journal Article|Review, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Immunity, Mucosal|Inflammatory Bowel Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",IBD in the time of corona - vigilance for immune-mediated diseases.,2020-09-08,Nature reviews. Gastroenterology &amp; hepatology,https://pubmed.ncbi.nlm.nih.gov/32555385,https://clinicaltrials.gov/ct2/show/NCT04354259
32555385,NCT04276688,Abstract,Journal Article|Review, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Immunity, Mucosal|Inflammatory Bowel Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",IBD in the time of corona - vigilance for immune-mediated diseases.,2020-09-08,Nature reviews. Gastroenterology &amp; hepatology,https://pubmed.ncbi.nlm.nih.gov/32555385,https://clinicaltrials.gov/ct2/show/NCT04276688
32559419,NCT04326920,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Review",Immunologic Factors|Granulocyte-Macrophage Colony-Stimulating Factor|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Disease Progression|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Immunologic Factors|Immunomodulation|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA",Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.,2020-08-31,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32559419,https://clinicaltrials.gov/ct2/show/NCT04326920
32560746,NCT04355364,Abstract,Clinical Trial Protocol|Letter|Multicenter Study,Aerosols|Recombinant Proteins|Deoxyribonuclease I|dornase alfa|NA,"Adult|Aerosols|Betacoronavirus|COVID-19|Coronavirus Infections|Deoxyribonuclease I|Humans|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Recombinant Proteins|Respiratory Distress Syndrome|SARS-CoV-2|Trachea|NA",Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial.,2020-07-07,Trials,https://pubmed.ncbi.nlm.nih.gov/32560746,https://clinicaltrials.gov/ct2/show/NCT04355364
32579195,NCT04326790,Abstract,Journal Article|Randomized Controlled Trial,Fibrin Fibrinogen Degradation Products|Troponin|Tubulin Modulators|fibrin fragment D|C-Reactive Protein|Colchicine|NA,"Aged|Aged, 80 and over|Betacoronavirus|C-Reactive Protein|COVID-19|Cause of Death|Colchicine|Coronavirus Infections|Diarrhea|Disease Progression|Female|Fibrin Fibrinogen Degradation Products|Greece|Hospitalization|Humans|Inflammation|Kaplan-Meier Estimate|Male|Middle Aged|Mortality|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Time Factors|Treatment Outcome|Troponin|Tubulin Modulators|NA",Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.,2020-07-02,JAMA network open,https://pubmed.ncbi.nlm.nih.gov/32579195,https://clinicaltrials.gov/ct2/show/NCT04326790
32586395,NCT04368156,Abstract,Clinical Trial Protocol|Letter, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Intensive Care Units|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Vagus Nerve Stimulation|NA","A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCoreÂ®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial&quot;.",2020-07-07,Trials,https://pubmed.ncbi.nlm.nih.gov/32586395,https://clinicaltrials.gov/ct2/show/NCT04368156
32586399,NCT04348513,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter|Multicenter Study",Triiodothyronine|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Double-Blind Method|Extracorporeal Membrane Oxygenation|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Triiodothyronine|Young Adult|NA",Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.,2020-07-07,Trials,https://pubmed.ncbi.nlm.nih.gov/32586399,https://clinicaltrials.gov/ct2/show/NCT04348513
32613089,NCT04380818,Abstract,Journal Article, , ,Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.,2020-09-28,Clinical and translational radiation oncology,https://pubmed.ncbi.nlm.nih.gov/32613089,https://clinicaltrials.gov/ct2/show/NCT04380818
32616063,NCT04410562,Abstract,Clinical Trial Protocol|Letter,Antiviral Agents|Hydroxychloroquine|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Chemoprevention|Coronavirus Infections|Double-Blind Method|Drug Administration Schedule|Female|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Pregnancy|Pregnancy Complications, Infectious|Protective Factors|Randomized Controlled Trials as Topic|Risk Assessment|Risk Factors|SARS-CoV-2|Severity of Illness Index|Spain|Time Factors|Treatment Outcome|Virus Shedding|NA",Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.,2020-07-10,Trials,https://pubmed.ncbi.nlm.nih.gov/32616063,https://clinicaltrials.gov/ct2/show/NCT04410562
32618282,NCT04307693,Abstract,Journal Article|Comment, ,"Betacoronavirus|COVID-19|Humans|Pandemics|Pneumonia, Viral|NA",Testing COVID-19 therapies to prevent progression of mild disease.,2020-12-04,The Lancet. Infectious diseases,https://pubmed.ncbi.nlm.nih.gov/32618282,https://clinicaltrials.gov/ct2/show/NCT04307693
32627860,NCT04368676,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Adult|Allied Health Personnel|Cognitive Behavioral Therapy|Female|Health Personnel|Humans|Male|Middle Aged|Mindfulness|Occupational Diseases|Randomized Controlled Trials as Topic|Resilience, Psychological|Stress, Psychological|NA",Psychological interventions to foster resilience in healthcare professionals.,2020-09-25,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/32627860,https://clinicaltrials.gov/ct2/show/NCT04368676
32641154,NCT04390464,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase IV|Letter","Antibodies, Monoclonal, Humanized|Azetidines|Immunologic Factors|Sulfonamides|ravulizumab|baricitinib|NA","Antibodies, Monoclonal, Humanized|Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Repositioning|Humans|Immunologic Factors|Intensive Care Units|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Sulfonamides|NA",Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.,2020-07-14,Trials,https://pubmed.ncbi.nlm.nih.gov/32641154,https://clinicaltrials.gov/ct2/show/NCT04390464
32641163,NCT04339816,Abstract,Clinical Trial Protocol|Journal Article|Multicenter Study,Hydroxychloroquine|Azithromycin|NA,"Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Drug Therapy, Combination|Humans|Hydroxychloroquine|Intensive Care Units|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|NA",Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.,2020-07-14,Trials,https://pubmed.ncbi.nlm.nih.gov/32641163,https://clinicaltrials.gov/ct2/show/NCT04339816
32641343,NCT04264533,Abstract,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Vitamins|Ascorbic Acid|NA,"Administration, Intravenous|Ascorbic Acid|Betacoronavirus|COVID-19|China|Coronavirus Infections|Cytokine Release Syndrome|Hospital Mortality|Humans|Intensive Care Units|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|Vitamins|NA",Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial.,2020-07-17,BMJ open,https://pubmed.ncbi.nlm.nih.gov/32641343,https://clinicaltrials.gov/ct2/show/NCT04264533
32648959,NCT04321421,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Betacoronavirus|COVID-19|Cause of Death|Coronavirus Infections|Early Termination of Clinical Trials|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Selection Bias|Severity of Illness Index|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-07-22,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/32648959,https://clinicaltrials.gov/ct2/show/NCT04321421
32658300,NCT04335123,Abstract,Journal Article, ,"Acute Kidney Injury|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",[COVID-19 and kidney disease].,2020-07-20,Lakartidningen,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04335123
32658300,NCT04311177,Abstract,Journal Article, ,"Acute Kidney Injury|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",[COVID-19 and kidney disease].,2020-07-20,Lakartidningen,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04311177
32658300,NCT04312009,Abstract,Journal Article, ,"Acute Kidney Injury|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",[COVID-19 and kidney disease].,2020-07-20,Lakartidningen,https://pubmed.ncbi.nlm.nih.gov/32658300,https://clinicaltrials.gov/ct2/show/NCT04312009
32660611,NCT04369469,Abstract,Clinical Trial Protocol|Letter,"Antibodies, Monoclonal, Humanized|Antiviral Agents|Complement Inactivating Agents|ravulizumab|NA","Administration, Intravenous|Antibodies, Monoclonal, Humanized|Antiviral Agents|Betacoronavirus|COVID-19|Clinical Trials, Phase III as Topic|Complement Inactivating Agents|Coronavirus Infections|Female|Host-Pathogen Interactions|Humans|Male|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Time Factors|Treatment Outcome|NA","A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.",2020-07-15,Trials,https://pubmed.ncbi.nlm.nih.gov/32660611,https://clinicaltrials.gov/ct2/show/NCT04369469
32663912,NCT04283461,Abstract,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|RNA, Messenger|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|mRNA-1273 vaccine|NA","Adult|Antibodies, Neutralizing|Antibodies, Viral|Antibody Formation|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunization, Secondary|Male|Pandemics|Pneumonia, Viral|RNA, Messenger|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Viral Vaccines|Young Adult|NA",An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.,2020-11-16,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32663912,https://clinicaltrials.gov/ct2/show/NCT04283461
32665041,NCT04368676,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter", ,"Betacoronavirus|COVID-19|Coronavirus Infections|Education, Distance|Feasibility Studies|Humans|Long-Term Care|Mind-Body Therapies|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiration|SARS-CoV-2|Yoga|NA",Breath Regulation and yogic Exercise An online Therapy for calm and Happiness (BREATH) for frontline hospital and long-term care home staff managing the COVID-19 pandemic: A structured summary of a study protocol for a feasibility study for a randomised controlled trial.,2020-08-18,Trials,https://pubmed.ncbi.nlm.nih.gov/32665041,https://clinicaltrials.gov/ct2/show/NCT04368676
32671131,NCT04252274,Abstract,Journal Article, , ,Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.,2020-09-28,Open forum infectious diseases,https://pubmed.ncbi.nlm.nih.gov/32671131,https://clinicaltrials.gov/ct2/show/NCT04252274
32673060,NCT04308668,Abstract,Journal Article|Multicenter Study|Randomized Controlled Trial,Antimalarials|Hydroxychloroquine|NA,"Adult|Antimalarials|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Female|Follow-Up Studies|Humans|Hydroxychloroquine|Male|Middle Aged|Outpatients|Pandemics|Pneumonia, Viral|Retrospective Studies|Risk Factors|SARS-CoV-2|Time Factors|NA",Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.,2020-10-27,Annals of internal medicine,https://pubmed.ncbi.nlm.nih.gov/32673060,https://clinicaltrials.gov/ct2/show/NCT04308668
32676976,NCT04251871,Abstract,Journal Article|Randomized Controlled Trial,"Drugs, Chinese Herbal|Interferon-alpha|Lopinavir|NA","Administration, Inhalation|Adult|COVID-19|China|Coronavirus Infections|Dose-Response Relationship, Drug|Drug Administration Schedule|Drugs, Chinese Herbal|Female|Follow-Up Studies|Humans|Integrative Medicine|Interferon-alpha|Lopinavir|Male|Middle Aged|Pandemics|Pneumonia, Viral|Risk Assessment|Severe Acute Respiratory Syndrome|Severity of Illness Index|Survival Rate|NA",Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.,2020-09-08,Chinese journal of integrative medicine,https://pubmed.ncbi.nlm.nih.gov/32676976,https://clinicaltrials.gov/ct2/show/NCT04251871
32678530,NCT04381936,Abstract,Journal Article, , ,Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.,2021-02-17,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32678530,https://clinicaltrials.gov/ct2/show/NCT04381936
32690074,NCT04361474,Abstract,Clinical Trial Protocol|Letter|Multicenter Study,Budesonide|NA,"Betacoronavirus|Budesonide|COVID-19|Coronavirus Infections|Humans|Olfaction Disorders|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|NA",Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.,2020-08-18,Trials,https://pubmed.ncbi.nlm.nih.gov/32690074,https://clinicaltrials.gov/ct2/show/NCT04361474
32702298,NCT04324606,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Analgesics, Non-Narcotic|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|Acetaminophen|NA","Acetaminophen|Adenoviruses, Simian|Adult|Analgesics, Non-Narcotic|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Genetic Vectors|Humans|Immunization, Secondary|Immunoglobulin G|Male|Pandemics|Pneumonia, Viral|SARS-CoV-2|Single-Blind Method|Spike Glycoprotein, Coronavirus|T-Lymphocytes|United Kingdom|Viral Vaccines|NA","Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.",2020-08-24,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32702298,https://clinicaltrials.gov/ct2/show/NCT04324606
32702299,NCT04341389,Abstract,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|NA","Adenoviridae|Adolescent|Adult|Age Factors|Aged|Aged, 80 and over|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|China|Coronavirus Infections|Double-Blind Method|Female|Genetic Vectors|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Viral Vaccines|Young Adult|NA","Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.",2020-08-24,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32702299,https://clinicaltrials.gov/ct2/show/NCT04341389
32706953,NCT04322123,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|Azithromycin|NA,"Adult|Aged|Aged, 80 and over|Antiviral Agents|Azithromycin|Betacoronavirus|Brazil|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Treatment Failure|NA",Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.,2020-12-01,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32706953,https://clinicaltrials.gov/ct2/show/NCT04322123
32736592,NCT04393246,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Letter","2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol|Benzhydryl Compounds|Glucosides|Immunologic Factors|Phenylpropionates|Pyridazines|ambrisentan|NA","Benzhydryl Compounds|Betacoronavirus|COVID-19|Coronavirus Infections|Glucosides|Humans|Immunologic Factors|Intensive Care Units|Pandemics|Phenylpropionates|Pneumonia, Viral|Pyridazines|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Standard of Care|NA",muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.,2020-08-18,Trials,https://pubmed.ncbi.nlm.nih.gov/32736592,https://clinicaltrials.gov/ct2/show/NCT04393246
32736597,NCT04363827,Abstract,Clinical Trial Protocol|Comparative Study|Journal Article|Observational Study,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Cluster Analysis|Coronavirus Infections|Female|Humans|Hydroxychloroquine|Male|Pandemics|Patient Reported Outcome Measures|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Telemedicine|NA",PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.,2020-08-18,Trials,https://pubmed.ncbi.nlm.nih.gov/32736597,https://clinicaltrials.gov/ct2/show/NCT04363827
32738255,NCT04433910,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Viral|Spike Glycoprotein, Coronavirus|NA","Animals|Antibodies, Viral|Betacoronavirus|COVID-19|Chlorocebus aethiops|Coronavirus Infections|Enzyme-Linked Immunosorbent Assay|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|Spike Glycoprotein, Coronavirus|Vero Cells|Viral Plaque Assay|NA",An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.,2020-09-07,Antiviral research,https://pubmed.ncbi.nlm.nih.gov/32738255,https://clinicaltrials.gov/ct2/show/NCT04433910
32738928,NCT04416399,Abstract,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04416399
32738928,NCT04331470,Abstract,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04331470
32738928,NCT04377711,Abstract,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04377711
32738928,NCT04330586,Abstract,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04330586
32738928,NCT04355637,Abstract,"Journal Article|Research Support, Non-U.S. Gov't",Adrenal Cortex Hormones|NA,"Administration, Inhalation|Adrenal Cortex Hormones|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?,2020-09-16,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32738928,https://clinicaltrials.gov/ct2/show/NCT04355637
32758441,NCT04296643,Abstract,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Disease Transmission, Infectious|Humans|Masks|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Use of facemasks during the COVID-19 pandemic.,2020-10-13,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32758441,https://clinicaltrials.gov/ct2/show/NCT04296643
32771032,NCT04338698,Abstract,Clinical Trial Protocol|Letter|Multicenter Study|Observational Study|Randomized Controlled Trial,Oseltamivir|Hydroxychloroquine|Azithromycin|NA,"Azithromycin|Betacoronavirus|COVID-19|Comorbidity|Coronavirus Infections|Humans|Hydroxychloroquine|Oseltamivir|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Research Design|SARS-CoV-2|NA","Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial.",2020-08-17,Trials,https://pubmed.ncbi.nlm.nih.gov/32771032,https://clinicaltrials.gov/ct2/show/NCT04338698
32771034,NCT04401202,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter", ,"Adolescent|Adult|Aged|Betacoronavirus|COVID-19|Coronavirus Infections|Dietary Supplements|Humans|Middle Aged|Nigella sativa|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|SARS-CoV-2|Standard of Care|Young Adult|NA","Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial.",2020-08-17,Trials,https://pubmed.ncbi.nlm.nih.gov/32771034,https://clinicaltrials.gov/ct2/show/NCT04401202
32779705,NCT04434131,Abstract,Clinical Trial|Journal Article,"Antibodies, Neutralizing|Antibodies, Viral|Immunoglobulin G|RNA, Viral|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|NA","Adult|Aged|Aged, 80 and over|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|Blood Donors|COVID-19|Cohort Studies|Coronavirus Infections|Female|Humans|Immunization, Passive|Immunoglobulin G|Male|Middle Aged|New Mexico|Pandemics|Pneumonia, Viral|RNA, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Treatment Outcome|NA",Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.,2020-11-02,The Journal of infectious diseases,https://pubmed.ncbi.nlm.nih.gov/32779705,https://clinicaltrials.gov/ct2/show/NCT04434131
32785213,NCT04368728,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Spike Glycoprotein, Coronavirus|Viral Vaccines|spike protein, SARS-CoV-2|NA","Adult|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunization, Passive|Immunoglobulin G|Male|Middle Aged|Pandemics|Pneumonia, Viral|Spike Glycoprotein, Coronavirus|Time Factors|Viral Vaccines|Young Adult|NA",PhaseÂ I/II study of COVID-19 RNA vaccine BNT162b1 in adults.,2020-10-29,Nature,https://pubmed.ncbi.nlm.nih.gov/32785213,https://clinicaltrials.gov/ct2/show/NCT04368728
32785710,NCT04343729,Abstract,Journal Article, , ,"Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.",2020-09-01,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,https://pubmed.ncbi.nlm.nih.gov/32785710,https://clinicaltrials.gov/ct2/show/NCT04343729
32788708,NCT04385095,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04385095
32788708,NCT04354259,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04354259
32788708,NCT04343976,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04343976
32788708,NCT04344600,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Azetidines|IL6 protein, human|Interferon Regulatory Factors|Interferon-alpha|Interleukin-1|Interleukin-6|Sulfonamides|Tumor Necrosis Factor-alpha|interferon-lambda, human|Interferon-beta|Interferons|JAK1 protein, human|Janus Kinase 1|baricitinib|NA","Azetidines|Betacoronavirus|COVID-19|Coronavirus Infections|Gene Expression Regulation|Humans|Immunity, Cellular|Immunity, Humoral|Interferon Regulatory Factors|Interferon-alpha|Interferon-beta|Interferons|Interleukin-1|Interleukin-6|Janus Kinase 1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severity of Illness Index|Sulfonamides|Tumor Necrosis Factor-alpha|NA",The type I interferon response in COVID-19: implications for treatment.,2020-10-06,Nature reviews. Immunology,https://pubmed.ncbi.nlm.nih.gov/32788708,https://clinicaltrials.gov/ct2/show/NCT04344600
32795330,NCT04345614,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Calcium Release Activated Calcium Channels|NA,"Aged|COVID-19|Calcium Release Activated Calcium Channels|Coronavirus Infections|Critical Care|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Severity of Illness Index|Standard of Care|Treatment Outcome|NA",Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial.,2020-08-20,"Critical care (London, England)",https://pubmed.ncbi.nlm.nih.gov/32795330,https://clinicaltrials.gov/ct2/show/NCT04345614
32799933,NCT04325061,Abstract,Clinical Trial Protocol|Journal Article|Multicenter Study,Dexamethasone|NA,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Dexamethasone|Humans|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Respiratory Distress Syndrome|SARS-CoV-2|Sample Size|NA",Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.,2020-08-25,Trials,https://pubmed.ncbi.nlm.nih.gov/32799933,https://clinicaltrials.gov/ct2/show/NCT04325061
32807209,NCT04381962,Abstract,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study",Anti-Bacterial Agents|Azithromycin|NA,"Anti-Bacterial Agents|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|Prospective Studies|Randomized Controlled Trials as Topic|Research Design|SARS-CoV-2|Severity of Illness Index|NA",A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.,2020-08-25,Trials,https://pubmed.ncbi.nlm.nih.gov/32807209,https://clinicaltrials.gov/ct2/show/NCT04381962
32815416,NCT04372589,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anticoagulants|Antiviral Agents|Heparin|NA,"Adolescent|Adult|Anticoagulants|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Dose-Response Relationship, Drug|Female|Heparin|Humans|Male|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombosis|Treatment Outcome|Young Adult|NA","Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.",2020-10-15,"Clinical trials (London, England)",https://pubmed.ncbi.nlm.nih.gov/32815416,https://clinicaltrials.gov/ct2/show/NCT04372589
32817460,NCT04412057,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal|IL6 protein, human|Interleukin-6|TNFSF14 protein, human|Tumor Necrosis Factor Ligand Superfamily Member 14|NA","Adult|Age Factors|Aged|Antibodies, Monoclonal|Betacoronavirus|COVID-19|Clinical Trials as Topic|Coronavirus Infections|Cytokine Release Syndrome|Hospitalization|Humans|Interleukin-6|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Tumor Necrosis Factor Ligand Superfamily Member 14|NA",Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.,2020-09-04,mSphere,https://pubmed.ncbi.nlm.nih.gov/32817460,https://clinicaltrials.gov/ct2/show/NCT04412057
32821939,NCT04292730,Abstract,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Hospitalization|Humans|Male|Middle Aged|Odds Ratio|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.,2020-09-29,JAMA,https://pubmed.ncbi.nlm.nih.gov/32821939,https://clinicaltrials.gov/ct2/show/NCT04292730
32828741,NCT04370288,Abstract,Case Reports|Journal Article,Ascorbic Acid|Methylene Blue|Acetylcysteine|NA,"Acetylcysteine|Ascorbic Acid|COVID-19|Clinical Trials, Phase I as Topic|Compassionate Use Trials|Coronavirus Infections|Critical Illness|Female|Humans|Hypoxia|Male|Methylene Blue|Middle Aged|Pandemics|Pneumonia, Viral|NA","Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.",2020-10-13,European journal of pharmacology,https://pubmed.ncbi.nlm.nih.gov/32828741,https://clinicaltrials.gov/ct2/show/NCT04370288
32829745,NCT04337541,Abstract,Journal Article|Randomized Controlled Trial, ,"Adult|Aged|COVID-19|Communicable Disease Control|Coronavirus Infections|Denmark|Female|Humans|Incidence|Infectious Disease Transmission, Vertical|Male|Masks|Middle Aged|Pandemics|Pneumonia, Viral|Primary Prevention|Public Health|Risk Assessment|World Health Organization|NA",Face masks for the prevention of COVID-19 - Rationale and design of the randomised controlled trial DANMASK-19.,2020-08-31,Danish medical journal,https://pubmed.ncbi.nlm.nih.gov/32829745,https://clinicaltrials.gov/ct2/show/NCT04337541
32838109,NCT04357730,Abstract,Journal Article, , ,STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study Design of the Phase IIa STARS Trial.,2020-09-28,Research and practice in thrombosis and haemostasis,https://pubmed.ncbi.nlm.nih.gov/32838109,https://clinicaltrials.gov/ct2/show/NCT04357730
32838353,NCT04252885,Abstract,Journal Article, , ,Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.,2021-01-10,"Med (New York, N.Y.)",https://pubmed.ncbi.nlm.nih.gov/32838353,https://clinicaltrials.gov/ct2/show/NCT04252885
32843098,NCT04395105,Abstract,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial,Glucocorticoids|Dexamethasone|NA,"Argentina|Betacoronavirus|COVID-19|Coronavirus Infections|Cross Infection|Delirium|Dexamethasone|Glucocorticoids|Humans|Mortality|Organ Dysfunction Scores|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Virus Shedding|NA",High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.,2020-09-03,Trials,https://pubmed.ncbi.nlm.nih.gov/32843098,https://clinicaltrials.gov/ct2/show/NCT04395105
32847626,NCT04420741,Abstract,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial,"THBD protein, human|Thrombomodulin|Vasodilator Agents|Iloprost|NA","Betacoronavirus|COVID-19|Coronavirus Infections|Denmark|Endothelium, Vascular|Humans|Iloprost|Infusions, Intravenous|Intensive Care Units|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Thrombomodulin|Vasodilator Agents|NA",The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.,2020-09-03,Trials,https://pubmed.ncbi.nlm.nih.gov/32847626,https://clinicaltrials.gov/ct2/show/NCT04420741
32876695,NCT04327401,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anti-Inflammatory Agents|Dexamethasone|NA,"Administration, Intravenous|Aged|Anti-Inflammatory Agents|Betacoronavirus|Brazil|COVID-19|Catheter-Related Infections|Coronavirus Infections|Dexamethasone|Early Termination of Clinical Trials|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|NA",Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.,2020-11-04,JAMA,https://pubmed.ncbi.nlm.nih.gov/32876695,https://clinicaltrials.gov/ct2/show/NCT04327401
32877576,NCT04368988,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Adjuvants, Immunologic|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Matrix-M|Saponins|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|spike glycoprotein, SARS-CoV|NA","Adjuvants, Immunologic|Adolescent|Adult|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunization Schedule|Immunogenicity, Vaccine|Immunoglobulin G|Male|Middle Aged|Nanoparticles|Pandemics|Saponins|Spike Glycoprotein, Coronavirus|Th1 Cells|Vaccines, Synthetic|Young Adult|NA",Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.,2020-12-17,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32877576,https://clinicaltrials.gov/ct2/show/NCT04368988
32888112,NCT04338841,Abstract,Journal Article, ,"Aged|Ambulatory Care|COVID-19|Coronavirus Infections|Delphi Technique|Hospitalization|Humans|Male|Middle Aged|Outpatients|Pandemics|Pneumonia, Viral|Risk Factors|Surveys and Questionnaires|NA",Outpatient management or hospitalization of patients with proven or suspected SARS-CoV-2 infection: the HOME-CoV rule.,2020-11-24,Internal and emergency medicine,https://pubmed.ncbi.nlm.nih.gov/32888112,https://clinicaltrials.gov/ct2/show/NCT04338841
32895056,NCT04445935,Abstract,Clinical Trial Protocol|Equivalence Trial|Letter,"Anticoagulants|Antithrombins|Fibrin Fibrinogen Degradation Products|Heparin, Low-Molecular-Weight|Hirudins|Peptide Fragments|Recombinant Proteins|fibrin fragment D|Heparin|bivalirudin|NA","Anticoagulants|Antithrombins|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Fibrin Fibrinogen Degradation Products|Heparin|Heparin, Low-Molecular-Weight|Hirudins|Humans|Pandemics|Partial Thromboplastin Time|Peptide Fragments|Pneumonia, Viral|Qatar|Recombinant Proteins|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|NA","Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial.",2020-09-10,Trials,https://pubmed.ncbi.nlm.nih.gov/32895056,https://clinicaltrials.gov/ct2/show/NCT04445935
32896291,NCT04436471,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Viral Vaccines|NA","Adenoviridae|Adult|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunity, Cellular|Immunity, Humoral|Immunization, Secondary|Immunoglobulin G|Injections, Intramuscular|Male|Pandemics|Pneumonia, Viral|Russia|SARS-CoV-2|Viral Vaccines|Young Adult|NA","Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.",2020-10-05,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32896291,https://clinicaltrials.gov/ct2/show/NCT04436471
32896291,NCT04437875,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","Ad5-nCoV vaccine|Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Viral Vaccines|NA","Adenoviridae|Adult|Antibodies, Neutralizing|Antibodies, Viral|Betacoronavirus|COVID-19|COVID-19 Vaccines|Coronavirus Infections|Female|Humans|Immunity, Cellular|Immunity, Humoral|Immunization, Secondary|Immunoglobulin G|Injections, Intramuscular|Male|Pandemics|Pneumonia, Viral|Russia|SARS-CoV-2|Viral Vaccines|Young Adult|NA","Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.",2020-10-05,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32896291,https://clinicaltrials.gov/ct2/show/NCT04437875
32896292,NCT04321278,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|Azithromycin|NA,"Aged|Antiviral Agents|Azithromycin|Betacoronavirus|Brazil|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Length of Stay|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiratory Therapy|SARS-CoV-2|Standard of Care|Treatment Outcome|NA",Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.,2020-10-14,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32896292,https://clinicaltrials.gov/ct2/show/NCT04321278
32903199,NCT04347681,Abstract,Journal Article, , ,Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study.,2020-10-23,JMIR research protocols,https://pubmed.ncbi.nlm.nih.gov/32903199,https://clinicaltrials.gov/ct2/show/NCT04347681
32907635,NCT04400799,Abstract,Clinical Trial Protocol|Letter,Anticoagulants|Enoxaparin|NA,"Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Enoxaparin|Equivalence Trials as Topic|Host-Pathogen Interactions|Humans|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombosis|Time Factors|Treatment Outcome|NA",Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.,2020-09-16,Trials,https://pubmed.ncbi.nlm.nih.gov/32907635,https://clinicaltrials.gov/ct2/show/NCT04400799
32907638,NCT04357808,Abstract,Clinical Trial Protocol|Letter,"Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|sarilumab|NA","Adult|Aged|Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Host-Pathogen Interactions|Humans|Male|Middle Aged|Pandemics|Patient Admission|Pneumonia, Viral|Proof of Concept Study|Randomized Controlled Trials as Topic|SARS-CoV-2|Spain|Time Factors|Treatment Outcome|Young Adult|NA",Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.,2020-09-16,Trials,https://pubmed.ncbi.nlm.nih.gov/32907638,https://clinicaltrials.gov/ct2/show/NCT04357808
32917259,NCT04399317,Abstract,Clinical Trial Protocol|Letter, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Feasibility Studies|Host-Pathogen Interactions|Humans|Lung|Pandemics|Pneumonia, Viral|Prospective Studies|Qatar|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Time Factors|Treatment Outcome|NA",Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial.,2020-09-16,Trials,https://pubmed.ncbi.nlm.nih.gov/32917259,https://clinicaltrials.gov/ct2/show/NCT04399317
32934758,NCT04327206,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Review",BCG Vaccine|Cytokines|NA,"BCG Vaccine|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coinfection|Coronavirus Infections|Cytokines|Diagnostic Errors|Disease Outbreaks|Humans|Influenza, Human|Middle East Respiratory Syndrome Coronavirus|Pandemics|Pneumonia, Viral|SARS Virus|SARS-CoV-2|Severe Acute Respiratory Syndrome|Severity of Illness Index|Tuberculosis|NA",Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.,2020-09-24,Canadian respiratory journal,https://pubmed.ncbi.nlm.nih.gov/32934758,https://clinicaltrials.gov/ct2/show/NCT04327206
32936948,NCT04352959,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anti-Infective Agents|Mouthwashes|Nasal Sprays|NA,"Anti-Infective Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Health Personnel|Humans|Infectious Disease Transmission, Patient-to-Professional|Mouth|Mouthwashes|Nasal Sprays|Nose|Occupational Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|Therapeutic Irrigation|NA",Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.,2020-09-30,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/32936948,https://clinicaltrials.gov/ct2/show/NCT04352959
32936949,NCT04364802,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anti-Infective Agents|Mouthwashes|Nasal Sprays|NA,"Anti-Infective Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Health Personnel|Humans|Infectious Disease Transmission, Patient-to-Professional|Mouth|Mouthwashes|Nasal Sprays|Nose|Occupational Diseases|Pandemics|Pneumonia, Viral|SARS-CoV-2|Therapeutic Irrigation|NA",Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection.,2020-09-30,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/32936949,https://clinicaltrials.gov/ct2/show/NCT04364802
32943115,NCT04373291,Abstract,Clinical Trial Protocol|Letter,BCG Vaccine|NA,"Absenteeism|BCG Vaccine|Betacoronavirus|COVID-19|Coronavirus Infections|Denmark|Female|Health Personnel|Humans|Male|Multicenter Studies as Topic|Occupational Health|Pandemics|Patient Admission|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Sick Leave|Single-Blind Method|Time Factors|Treatment Outcome|Vaccination|NA",Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.,2020-09-23,Trials,https://pubmed.ncbi.nlm.nih.gov/32943115,https://clinicaltrials.gov/ct2/show/NCT04373291
32951151,NCT04343261,Abstract,Journal Article, , ,Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseÂ II Clinical Trial.,2021-01-29,Infectious diseases and therapy,https://pubmed.ncbi.nlm.nih.gov/32951151,https://clinicaltrials.gov/ct2/show/NCT04343261
32958495,NCT04315948,Abstract,"Adaptive Clinical Trial|Clinical Trial Protocol|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Ritonavir|Alanine|Interferon beta-1a|NA,"Adenosine Monophosphate|Adult|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Drug Therapy, Combination|Early Warning Score|Extracorporeal Membrane Oxygenation|Hospital Mortality|Hospitalization|Humans|Hydroxychloroquine|Interferon beta-1a|Length of Stay|Lopinavir|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|Respiration, Artificial|Ritonavir|SARS-CoV-2|Standard of Care|Treatment Outcome|NA","Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.",2020-10-05,BMJ open,https://pubmed.ncbi.nlm.nih.gov/32958495,https://clinicaltrials.gov/ct2/show/NCT04315948
32983830,NCT04343261,Abstract,Journal Article, , ,Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseÂ II Clinical Trial.,2020-11-23,Infectious diseases and therapy,https://pubmed.ncbi.nlm.nih.gov/32983830,https://clinicaltrials.gov/ct2/show/NCT04343261
32991794,NCT04283461,Abstract,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|mRNA-1273 vaccine|NA","Aged|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Dose-Response Relationship, Drug|Female|Humans|Male|Middle Aged|Neutralization Tests|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|NA",Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.,2020-12-23,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32991794,https://clinicaltrials.gov/ct2/show/NCT04283461
32993779,NCT04321928,Abstract,Clinical Trial Protocol|Journal Article, ,"Adaptive Clinical Trials as Topic|Age Factors|Aged|Aged, 80 and over|Alcohol Drinking|Betacoronavirus|COVID-19|Coronavirus Infections|Exercise|Feeding Behavior|Female|Health Education|Health Knowledge, Attitudes, Practice|Health Status|Host-Pathogen Interactions|Humans|Hungary|Male|Mental Health|Middle Aged|Pandemics|Pneumonia, Viral|Pragmatic Clinical Trials as Topic|Protective Factors|Risk Assessment|Risk Factors|Risk Reduction Behavior|SARS-CoV-2|Smoking|NA",Personalised health education against health damage of COVID-19 epidemic in the elderly Hungarian population (PROACTIVE-19): protocol of an adaptive randomised controlled clinical trial.,2020-10-13,Trials,https://pubmed.ncbi.nlm.nih.gov/32993779,https://clinicaltrials.gov/ct2/show/NCT04321928
32999432,NCT04394416,Abstract,"Letter|Research Support, N.I.H., Extramural",Antiviral Agents|Protein Kinase Inhibitors|Pyrazoles|asciminib|Niacinamide|Imatinib Mesylate|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Caco-2 Cells|Coronavirus Infections|Drug Repositioning|Humans|Imatinib Mesylate|Inhibitory Concentration 50|Niacinamide|Pandemics|Pneumonia, Viral|Protein Kinase Inhibitors|Pyrazoles|Randomized Controlled Trials as Topic|SARS-CoV-2|Virus Internalization|Virus Replication|NA",Imatinib is not a potent anti-SARS-CoV-2 drug.,2020-11-05,Leukemia,https://pubmed.ncbi.nlm.nih.gov/32999432,https://clinicaltrials.gov/ct2/show/NCT04394416
33001138,NCT04329923,Abstract,Journal Article|Multicenter Study|Randomized Controlled Trial,Hydroxychloroquine|NA,"Adult|COVID-19|Cross Infection|Double-Blind Method|Female|Hospitals, Urban|Humans|Hydroxychloroquine|Incidence|Male|Pennsylvania|Personnel, Hospital|Pre-Exposure Prophylaxis|SARS-CoV-2|NA",Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.,2021-02-05,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/33001138,https://clinicaltrials.gov/ct2/show/NCT04329923
33015643,NCT04333420,Abstract,Journal Article, , ,"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.",2020-11-27,The Lancet Rheumatology,https://pubmed.ncbi.nlm.nih.gov/33015643,https://clinicaltrials.gov/ct2/show/NCT04333420
33031652,NCT04381936,Abstract,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Antiviral Agents|Hydroxychloroquine|NA,"Aged|Aged, 80 and over|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Treatment Failure|NA",Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.,2020-12-01,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33031652,https://clinicaltrials.gov/ct2/show/NCT04381936
33031955,NCT04317092,Abstract,Clinical Trial Protocol|Journal Article,"Antibodies, Monoclonal, Humanized|Immunologic Factors|Receptors, Interleukin-6|tocilizumab|NA","Administration, Intravenous|Adult|Antibodies, Monoclonal, Humanized|COVID-19|Clinical Trials, Phase II as Topic|Cytokine Release Syndrome|Drug Administration Schedule|Drug Monitoring|Female|Humans|Immunologic Factors|Male|Multicenter Studies as Topic|Pneumonia, Viral|Receptors, Interleukin-6|Treatment Outcome|NA",TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.,2020-12-11,Contemporary clinical trials,https://pubmed.ncbi.nlm.nih.gov/33031955,https://clinicaltrials.gov/ct2/show/NCT04317092
33043164,NCT04317092,Abstract,Journal Article, , ,"A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan.",2020-12-22,Contemporary clinical trials communications,https://pubmed.ncbi.nlm.nih.gov/33043164,https://clinicaltrials.gov/ct2/show/NCT04317092
33044747,NCT04342182,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04342182
33044747,NCT04357106,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04357106
33044747,NCT04321421,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04321421
33044747,NCT04441424,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04441424
33044747,NCT04343261,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04343261
33044747,NCT04434131,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04434131
33044747,NCT04340050,Abstract,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Bias|COVID-19|Cause of Death|Coronavirus Infections|Humans|Immunization, Passive|Non-Randomized Controlled Trials as Topic|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Treatment Outcome|NA",Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.,2020-10-21,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33044747,https://clinicaltrials.gov/ct2/show/NCT04340050
33050459,NCT04555096,Abstract,Journal Article, , ,May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?,2020-11-03,"Antioxidants (Basel, Switzerland)",https://pubmed.ncbi.nlm.nih.gov/33050459,https://clinicaltrials.gov/ct2/show/NCT04555096
33050924,NCT04356495,Abstract,"Clinical Trial, Phase III|Letter|Randomized Controlled Trial",Amides|Antihypertensive Agents|Antimalarials|Antiviral Agents|Protein Kinase Inhibitors|Pyrazines|Hydroxychloroquine|Imatinib Mesylate|favipiravir|Telmisartan|NA,"Aged|Aged, 80 and over|Amides|Antihypertensive Agents|Antimalarials|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Tolerance|Feasibility Studies|France|Hospitalization|Humans|Hydroxychloroquine|Imatinib Mesylate|Luxembourg|Outpatients|Pandemics|Pneumonia, Viral|Protein Kinase Inhibitors|Pyrazines|Risk Reduction Behavior|SARS-CoV-2|Telmisartan|Therapies, Investigational|Treatment Outcome|NA",Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).,2020-11-03,Trials,https://pubmed.ncbi.nlm.nih.gov/33050924,https://clinicaltrials.gov/ct2/show/NCT04356495
33050947,NCT04445467,Abstract,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial",Amides|Antiviral Agents|Biomarkers|Placebos|Pyrazines|favipiravir|NA,"Amides|Antiviral Agents|Australia|Betacoronavirus|Biomarkers|COVID-19|Clinical Protocols|Coronavirus Infections|Female|Hospitalization|Humans|Male|Pandemics|Placebos|Pneumonia, Viral|Pyrazines|SARS-CoV-2|Safety|Treatment Outcome|NA",An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.,2020-11-03,Trials,https://pubmed.ncbi.nlm.nih.gov/33050947,https://clinicaltrials.gov/ct2/show/NCT04445467
33053279,NCT04368728,Abstract,"Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|BNT162 vaccine|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Female|Humans|Injections, Intramuscular|Male|Middle Aged|Neutralization Tests|SARS-CoV-2|Single-Blind Method|Spike Glycoprotein, Coronavirus|Young Adult|NA",Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.,2020-12-23,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33053279,https://clinicaltrials.gov/ct2/show/NCT04368728
33066761,NCT04343963,Abstract,Clinical Trial Protocol|Journal Article,Cholinesterase Inhibitors|Pyridostigmine Bromide|NA,"Adult|Betacoronavirus|COVID-19|Cholinesterase Inhibitors|Coronavirus Infections|Humans|Inflammation|Lung|Pandemics|Pneumonia, Viral|Pyridostigmine Bromide|Respiration, Artificial|SARS-CoV-2|NA","A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.",2020-10-26,BMC infectious diseases,https://pubmed.ncbi.nlm.nih.gov/33066761,https://clinicaltrials.gov/ct2/show/NCT04343963
33080005,NCT04346355,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Receptors, Interleukin-6|C-Reactive Protein|tocilizumab|NA","Aged|Antibodies, Monoclonal, Humanized|Blood Gas Analysis|C-Reactive Protein|COVID-19|Disease Progression|Early Termination of Clinical Trials|Female|Fever|Hospital Mortality|Hospitalization|Humans|Intensive Care Units|Italy|Male|Medical Futility|Middle Aged|Receptors, Interleukin-6|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|NA",Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.,2021-01-15,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/33080005,https://clinicaltrials.gov/ct2/show/NCT04346355
33080017,NCT04331808,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Adrenal Cortex Hormones|Anti-Bacterial Agents|Antibodies, Monoclonal, Humanized|Anticoagulants|Antiviral Agents|Receptors, Interleukin-6|Vasoconstrictor Agents|tocilizumab|NA","Adrenal Cortex Hormones|Aged|Anti-Bacterial Agents|Antibodies, Monoclonal, Humanized|Anticoagulants|Antiviral Agents|COVID-19|Disease Progression|Female|Hospital Mortality|Hospitalization|Humans|Intubation, Intratracheal|Male|Middle Aged|Mortality|Noninvasive Ventilation|Oxygen Inhalation Therapy|Receptors, Interleukin-6|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Severity of Illness Index|Vasoconstrictor Agents|NA",Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.,2021-01-15,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/33080017,https://clinicaltrials.gov/ct2/show/NCT04331808
33081817,NCT04322396,Abstract,Journal Article|Multicenter Study|Randomized Controlled Trial,Anti-Bacterial Agents|Antimalarials|Placebos|Hydroxychloroquine|Azithromycin|NA,"Aged|Anti-Bacterial Agents|Antibiotic Prophylaxis|Antimalarials|Azithromycin|Betacoronavirus|COVID-19|Case-Control Studies|Coronavirus Infections|Denmark|Double-Blind Method|Drug Therapy, Combination|Female|Hospital Mortality|Hospitalization|Humans|Hydroxychloroquine|Intensive Care Units|Intention to Treat Analysis|Male|Noninvasive Ventilation|Pandemics|Placebos|Pneumonia, Viral|Risk Reduction Behavior|SARS-CoV-2|NA",Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.,2020-11-03,Trials,https://pubmed.ncbi.nlm.nih.gov/33081817,https://clinicaltrials.gov/ct2/show/NCT04322396
33082342,NCT04316377,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|NA,"Aged|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|Viral Load|NA",A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.,2020-11-02,Nature communications,https://pubmed.ncbi.nlm.nih.gov/33082342,https://clinicaltrials.gov/ct2/show/NCT04316377
33083026,NCT04436276,Abstract,Journal Article, , ,Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.,2020-10-22,NPJ vaccines,https://pubmed.ncbi.nlm.nih.gov/33083026,https://clinicaltrials.gov/ct2/show/NCT04436276
33085857,NCT04356937,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|IL6R protein, human|Receptors, Interleukin-6|tocilizumab|NA","Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Boston|COVID-19|Disease Progression|Double-Blind Method|Female|Humans|Intubation|Male|Middle Aged|Receptors, Interleukin-6|Respiratory Therapy|Treatment Failure|Young Adult|NA",Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.,2020-12-17,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33085857,https://clinicaltrials.gov/ct2/show/NCT04356937
33087150,NCT04317092,Abstract,"Clinical Trial, Phase II|Journal Article|Multicenter Study","Antibodies, Monoclonal, Humanized|tocilizumab|NA","Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Betacoronavirus|COVID-19|Cohort Studies|Coronavirus Infections|Female|Humans|Italy|Male|Middle Aged|Mortality|Off-Label Use|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|Validation Studies as Topic|NA",Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.,2020-10-30,Journal of translational medicine,https://pubmed.ncbi.nlm.nih.gov/33087150,https://clinicaltrials.gov/ct2/show/NCT04317092
33092632,NCT04374526,Abstract,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Letter|Randomized Controlled Trial", ,"Aged|Aged, 80 and over|Betacoronavirus|Blood Transfusion|COVID-19|Comorbidity|Coronavirus Infections|Disease Progression|Female|Humans|Immunization, Passive|Informed Consent|Italy|Male|Mortality|Pandemics|Pneumonia|Pneumonia, Viral|SARS-CoV-2|Tomography, X-Ray Computed|Viral Load|NA",&quot;Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial&quot;.,2020-11-03,Trials,https://pubmed.ncbi.nlm.nih.gov/33092632,https://clinicaltrials.gov/ct2/show/NCT04374526
33106167,NCT04403477,Abstract,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial", ,"Bangladesh|Betacoronavirus|Blood Transfusion|COVID-19|Coronavirus Infections|Dose-Response Relationship, Immunologic|Female|Hospital Mortality|Humans|Immunization, Passive|Male|Pandemics|Patient Discharge|Pneumonia, Viral|SARS-CoV-2|Safety|Severity of Illness Index|Time Factors|Treatment Outcome|Ventilators, Mechanical|NA","Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.",2020-11-02,Trials,https://pubmed.ncbi.nlm.nih.gov/33106167,https://clinicaltrials.gov/ct2/show/NCT04403477
33108622,NCT04389840,Abstract,Journal Article, , ,"Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.",2021-02-18,Advances in therapy,https://pubmed.ncbi.nlm.nih.gov/33108622,https://clinicaltrials.gov/ct2/show/NCT04389840
33110944,NCT04328493,Abstract,Journal Article, , ,A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.,2020-10-29,Wellcome open research,https://pubmed.ncbi.nlm.nih.gov/33110944,https://clinicaltrials.gov/ct2/show/NCT04328493
33113295,NCT04427501,Abstract,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Immunologic Factors|RNA, Viral|bamlanivimab|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|COVID-19|Dose-Response Relationship, Drug|Double-Blind Method|Female|Hospitalization|Humans|Immunologic Factors|Male|Middle Aged|Outpatients|RNA, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Severity of Illness Index|Viral Load|Young Adult|NA",SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.,2021-02-03,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33113295,https://clinicaltrials.gov/ct2/show/NCT04427501
33115543,NCT04394416,Abstract,Clinical Trial Protocol|Letter,Protein Kinase Inhibitors|Imatinib Mesylate|NA,"Administration, Oral|Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Care|Dose-Response Relationship, Drug|Double-Blind Method|Drug Monitoring|Female|Humans|Imatinib Mesylate|Male|Pandemics|Pneumonia, Viral|Protein Kinase Inhibitors|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|NA",Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.,2020-11-05,Trials,https://pubmed.ncbi.nlm.nih.gov/33115543,https://clinicaltrials.gov/ct2/show/NCT04394416
33129363,NCT04392973,Abstract,Clinical Trial Protocol|Letter,Amides|Antiviral Agents|Pyrazines|Hydroxychloroquine|favipiravir|NA,"Amides|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Host-Pathogen Interactions|Humans|Hydroxychloroquine|Inpatients|Male|Multicenter Studies as Topic|Pandemics|Pneumonia, Viral|Pyrazines|Randomized Controlled Trials as Topic|SARS-CoV-2|Saudi Arabia|Time Factors|Treatment Outcome|NA",A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.,2020-11-04,Trials,https://pubmed.ncbi.nlm.nih.gov/33129363,https://clinicaltrials.gov/ct2/show/NCT04392973
33138848,NCT04352959,Abstract,Clinical Trial Protocol|Letter,Antiviral Agents|Mouthwashes|beta-Cyclodextrins|betadex|NA,"Adult|Antiviral Agents|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Drug Monitoring|Female|Humans|Male|Mouthwashes|Nasal Cavity|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Saliva|Treatment Outcome|Viral Load|beta-Cyclodextrins|NA",Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial.,2020-11-09,Trials,https://pubmed.ncbi.nlm.nih.gov/33138848,https://clinicaltrials.gov/ct2/show/NCT04352959
33138867,NCT04521309,Abstract,Clinical Trial Protocol|Letter,"Immunoglobulins, Intravenous|Immunologic Factors|NA","Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Female|Humans|Immunization, Passive|Immunoglobulins, Intravenous|Immunologic Factors|Male|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|NA",Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.,2020-11-09,Trials,https://pubmed.ncbi.nlm.nih.gov/33138867,https://clinicaltrials.gov/ct2/show/NCT04521309
33139139,NCT04368988,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Adjuvants, Immunologic|Antibodies, Neutralizing|COVID-19 Vaccines|Immune Sera|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|recombinant SARS-CoV-2 vaccine NVX-cov2373|spike protein, SARS-CoV-2|ACE2 protein, human|Angiotensin-Converting Enzyme 2|NA","Adjuvants, Immunologic|Adolescent|Adult|Aged|Angiotensin-Converting Enzyme 2|Animals|Antibodies, Neutralizing|COVID-19|COVID-19 Vaccines|Chlorocebus aethiops|Female|Humans|Immune Sera|Macaca fascicularis|Male|Middle Aged|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Vaccines, Synthetic|Vero Cells|Viral Load|Young Adult|NA",NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.,2020-12-11,Vaccine,https://pubmed.ncbi.nlm.nih.gov/33139139,https://clinicaltrials.gov/ct2/show/NCT04368988
33148977,NCT04492475,Abstract,Journal Article|Review, ,"COVID-19|Humans|Immune Tolerance|Kidney Failure, Chronic|Organ Transplantation|SARS-CoV-2|NA",COVID-19 and Solid Organ Transplantation: A Review Article.,2021-01-06,Transplantation,https://pubmed.ncbi.nlm.nih.gov/33148977,https://clinicaltrials.gov/ct2/show/NCT04492475
33148977,NCT04401579,Abstract,Journal Article|Review, ,"COVID-19|Humans|Immune Tolerance|Kidney Failure, Chronic|Organ Transplantation|SARS-CoV-2|NA",COVID-19 and Solid Organ Transplantation: A Review Article.,2021-01-06,Transplantation,https://pubmed.ncbi.nlm.nih.gov/33148977,https://clinicaltrials.gov/ct2/show/NCT04401579
33153145,NCT04557605,Abstract,Journal Article|Randomized Controlled Trial, ,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Exercise|Exercise Test|Female|Humans|Male|Masks|Oximetry|Oxygen Consumption|Pandemics|Pneumonia, Viral|SARS-CoV-2|Young Adult|NA",Wearing of Cloth or Disposable Surgical Face Masks has no Effect on Vigorous Exercise Performance in Healthy Individuals.,2020-11-23,International journal of environmental research and public health,https://pubmed.ncbi.nlm.nih.gov/33153145,https://clinicaltrials.gov/ct2/show/NCT04557605
33153629,NCT04351152,Abstract,"Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Granulocyte-Macrophage Colony-Stimulating Factor|lenzilumab|NA","Aged|Antibodies, Monoclonal, Humanized|COVID-19|Dose-Response Relationship, Drug|Female|Granulocyte-Macrophage Colony-Stimulating Factor|Humans|Infusions, Intravenous|Male|Middle Aged|Pandemics|SARS-CoV-2|Treatment Outcome|NA",GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.,2020-12-08,Mayo Clinic proceedings,https://pubmed.ncbi.nlm.nih.gov/33153629,https://clinicaltrials.gov/ct2/show/NCT04351152
33157937,NCT04428099,Abstract,Clinical Trial Protocol|Journal Article, ,"COVID-19|Cognitive Behavioral Therapy|Coronavirus Infections|Depressive Disorder, Treatment-Resistant|Health Promotion|Healthy Lifestyle|Humans|Mindfulness|Pandemics|Pneumonia, Viral|Pragmatic Clinical Trials as Topic|Quality of Life|Surveys and Questionnaires|Telemedicine|NA",Effectiveness of a healthy lifestyle promotion program as adjunctive teletherapy for treatment-resistant major depression during COVID 19 pandemic: A randomized clinical trial protocol.,2020-11-18,Medicine,https://pubmed.ncbi.nlm.nih.gov/33157937,https://clinicaltrials.gov/ct2/show/NCT04428099
33165503,NCT04412538,Abstract,Journal Article, , ,"Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.",2020-12-10,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,https://pubmed.ncbi.nlm.nih.gov/33165503,https://clinicaltrials.gov/ct2/show/NCT04412538
33165621,NCT04332991,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural",Hydroxychloroquine|NA,Adult|Aged|COVID-19|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Treatment Failure|NA,Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.,2020-12-11,JAMA,https://pubmed.ncbi.nlm.nih.gov/33165621,https://clinicaltrials.gov/ct2/show/NCT04332991
33166179,NCT04329832,Abstract,Journal Article, , ,"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.",2020-12-07,Annals of the American Thoracic Society,https://pubmed.ncbi.nlm.nih.gov/33166179,https://clinicaltrials.gov/ct2/show/NCT04329832
33175911,NCT04366882,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","RNA, Viral|NA","Aged|Autopsy|Belgium|Betacoronavirus|COVID-19|Cause of Death|Coronavirus Infections|Female|Humans|Male|Pandemics|Pneumonia, Viral|Prospective Studies|RNA, Viral|SARS-CoV-2|Tomography, X-Ray Computed|NA",The clinical value of minimal invasive autopsy in COVID-19 patients.,2020-11-18,PloS one,https://pubmed.ncbi.nlm.nih.gov/33175911,https://clinicaltrials.gov/ct2/show/NCT04366882
33176886,NCT04487990,Abstract,Clinical Trial Protocol|Letter,Anticoagulants|Fibrin Fibrinogen Degradation Products|Hemoglobins|fibrin fragment D|Heparin|NA,"Acute Kidney Injury|Adult|Anticoagulants|Blood Coagulation|COVID-19|Coronavirus Infections|Drug Monitoring|Female|Fibrin Fibrinogen Degradation Products|Hemoglobins|Hemorrhage|Heparin|Humans|Male|Outcome Assessment, Health Care|Pandemics|Pneumonia, Viral|Randomized Controlled Trials as Topic|Renal Dialysis|Risk Adjustment|Thrombocytopenia|Thrombosis|NA",Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.,2020-11-23,Trials,https://pubmed.ncbi.nlm.nih.gov/33176886,https://clinicaltrials.gov/ct2/show/NCT04487990
33177145,NCT04395144,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04395144
33177145,NCT04391140,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04391140
33177145,NCT04347941,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04347941
33177145,NCT04358939,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|Cannula|Coronavirus Infections|Equivalence Trials as Topic|Humans|Hypoxia|Meta-Analysis as Topic|Oxygen Inhalation Therapy|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Randomized Controlled Trials as Topic|SARS-CoV-2|Wakefulness|NA",Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial.,2020-11-19,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33177145,https://clinicaltrials.gov/ct2/show/NCT04358939
33180097,NCT04342663,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Fluvoxamine|NA,Adult|COVID-19|Clinical Deterioration|Double-Blind Method|Female|Fluvoxamine|Humans|Illinois|Male|Middle Aged|Missouri|Outpatients|Treatment Outcome|NA,Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.,2020-12-18,JAMA,https://pubmed.ncbi.nlm.nih.gov/33180097,https://clinicaltrials.gov/ct2/show/NCT04342663
33184083,NCT04364022,Abstract,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't",Antiviral Agents|Drug Combinations|lopinavir-ritonavir drug combination|Lopinavir|Ritonavir|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Combinations|Humans|Lopinavir|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Switzerland|NA",Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.,2020-11-19,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33184083,https://clinicaltrials.gov/ct2/show/NCT04364022
33184146,NCT04459247,Abstract,Journal Article, , ,"Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).",2020-11-13,Postgraduate medical journal,https://pubmed.ncbi.nlm.nih.gov/33184146,https://clinicaltrials.gov/ct2/show/NCT04459247
33186055,NCT04435184,Abstract,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural",Troponin|NA,"Aged|COVID-19|Disease-Free Survival|Female|Heart Injuries|Humans|Male|Middle Aged|Myocardium|Prevalence|Registries|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Severity of Illness Index|Survival Rate|Troponin|NA",Myocardial Injury in Severe COVID-19 Compared With Non-COVID-19 Acute Respiratory Distress Syndrome.,2021-02-15,Circulation,https://pubmed.ncbi.nlm.nih.gov/33186055,https://clinicaltrials.gov/ct2/show/NCT04435184
33189161,NCT04385095,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.",2021-02-10,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/33189161,https://clinicaltrials.gov/ct2/show/NCT04385095
33190086,NCT04374149,Abstract,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|COVID-19|Critical Illness|Cytokine Release Syndrome|Female|Humans|Male|Middle Aged|Oxygen Inhalation Therapy|Pilot Projects|Plasma Exchange|Prospective Studies|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Severity of Illness Index|NA",Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.,2021-01-11,Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/33190086,https://clinicaltrials.gov/ct2/show/NCT04374149
33192504,NCT04487964,Abstract,Journal Article, , ,Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of <i>Glycyrrhiza glabra</i> L. (Licorice).,2020-11-17,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33192504,https://clinicaltrials.gov/ct2/show/NCT04487964
33196449,NCT04468893,Abstract,Journal Article, , ,A Self-Administered Multicomponent Web-Based Mental Health Intervention for the Mexican Population During the COVID-19 Pandemic: Protocol for a Randomized Controlled Trial.,2020-12-07,JMIR research protocols,https://pubmed.ncbi.nlm.nih.gov/33196449,https://clinicaltrials.gov/ct2/show/NCT04468893
33203440,NCT04455360,Abstract,Clinical Trial Protocol|Letter, ,"Adult|Anxiety|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Depression|Eye Movement Desensitization Reprocessing|Feasibility Studies|Female|Home Care Services, Hospital-Based|Humans|Internet-Based Intervention|Male|Pandemics|Pneumonia, Viral|Psychological Techniques|Quality of Life|Randomized Controlled Trials as Topic|SARS-CoV-2|Stress Disorders, Post-Traumatic|NA",CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial.,2020-11-23,Trials,https://pubmed.ncbi.nlm.nih.gov/33203440,https://clinicaltrials.gov/ct2/show/NCT04455360
33204764,NCT04328467,Abstract,Journal Article, , ,Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19.,2020-12-30,Open forum infectious diseases,https://pubmed.ncbi.nlm.nih.gov/33204764,https://clinicaltrials.gov/ct2/show/NCT04328467
33205991,NCT04337541,Abstract,Journal Article, , ,Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.,2021-01-21,Annals of internal medicine,https://pubmed.ncbi.nlm.nih.gov/33205991,https://clinicaltrials.gov/ct2/show/NCT04337541
33212440,NCT04341922,Abstract,Journal Article, , ,Brief Online Cognitive Behavioural Intervention for Dysfunctional Worry Related to the COVID-19 Pandemic: A Randomised Controlled Trial.,2021-01-14,Psychotherapy and psychosomatics,https://pubmed.ncbi.nlm.nih.gov/33212440,https://clinicaltrials.gov/ct2/show/NCT04341922
33213529,NCT04382755,Abstract,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial",Anti-Bacterial Agents|Complement C5|Ceftriaxone|Oxygen|NA,"Acute Disease|Adult|Anti-Bacterial Agents|Belgium|Betacoronavirus|COVID-19|Case-Control Studies|Ceftriaxone|Complement C5|Coronavirus Infections|Cytokine Release Syndrome|Drug Therapy, Combination|Humans|Hypoxia|Infusions, Intravenous|Injections, Subcutaneous|Oxygen|Pandemics|Pneumonia, Viral|Prospective Studies|Respiratory Insufficiency|SARS-CoV-2|Safety|Treatment Outcome|NA",Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.,2020-11-26,Trials,https://pubmed.ncbi.nlm.nih.gov/33213529,https://clinicaltrials.gov/ct2/show/NCT04382755
33217362,NCT04352608,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Immunoglobulin G|Immunoglobulin M|Vaccines, Inactivated|NA","Adolescent|Adult|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|China|Female|Healthy Volunteers|Humans|Immunization Schedule|Immunogenicity, Vaccine|Immunoglobulin G|Immunoglobulin M|Male|Middle Aged|SARS-CoV-2|Seroconversion|Vaccination|Vaccines, Inactivated|Young Adult|NA","Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.",2021-02-15,The Lancet. Infectious diseases,https://pubmed.ncbi.nlm.nih.gov/33217362,https://clinicaltrials.gov/ct2/show/NCT04352608
33220855,NCT04400838,Abstract,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|Immunoglobulin G|ChAdOx1 COVID-19 vaccine|NA,"Adolescent|Adult|Age Factors|Aged|Aged, 80 and over|COVID-19|COVID-19 Vaccines|Female|Humans|Immunization, Secondary|Immunogenicity, Vaccine|Immunoglobulin G|Male|Middle Aged|SARS-CoV-2|Single-Blind Method|Young Adult|NA","Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.",2020-12-31,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/33220855,https://clinicaltrials.gov/ct2/show/NCT04400838
33225960,NCT04449380,Abstract,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial",Antiviral Agents|Oxygen|Interferon beta-1a|NA,"Adult|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Data Management|Female|Humans|Injections, Subcutaneous|Interferon beta-1a|Italy|Length of Stay|Male|Mortality|Oxygen|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|Viral Load|NA",Interferon Î²-1a (IFNÎ²-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial.,2020-11-26,Trials,https://pubmed.ncbi.nlm.nih.gov/33225960,https://clinicaltrials.gov/ct2/show/NCT04449380
33225989,NCT04495816,Abstract,Letter|Randomized Controlled Trial,"Fatty Acids, Omega-3|Placebos|NA","Betacoronavirus|COVID-19|Case-Control Studies|Coronavirus Infections|Dietary Supplements|Double-Blind Method|Fatty Acids, Omega-3|Humans|New York|Olfaction Disorders|Pandemics|Placebos|Pneumonia, Viral|SARS-CoV-2|Smell|NA",Letter to the editor: Study Summary - Randomized Control Trial of Omega-3 Fatty Acid Supplementation for the Treatment of COVID-19 Related Olfactory Dysfunction.,2020-11-26,Trials,https://pubmed.ncbi.nlm.nih.gov/33225989,https://clinicaltrials.gov/ct2/show/NCT04495816
33225990,NCT04477655,Abstract,Letter|Randomized Controlled Trial,Oxygen|NA,"Acute Disease|Adult|Betacoronavirus|COVID-19|Cannula|Case-Control Studies|Coronavirus Infections|Female|Hospitalization|Humans|Intubation, Intratracheal|Male|Mexico|Oxygen|Pandemics|Patient Positioning|Pneumonia, Viral|Prone Position|Respiratory Insufficiency|SARS-CoV-2|NA","Prone positioning in non-intubated patients with COVID-19 associated acute respiratory failure, the PRO-CARF trial: A structured summary of a study protocol for a randomised controlled trial.",2020-11-26,Trials,https://pubmed.ncbi.nlm.nih.gov/33225990,https://clinicaltrials.gov/ct2/show/NCT04477655
33225995,NCT04438070,Abstract,Comparative Study|Letter|Randomized Controlled Trial, ,"Adult|Betacoronavirus|COVID-19|Coronavirus Infections|Early Diagnosis|Female|Homeless Persons|Humans|Male|Mass Screening|Ontario|Pandemics|Patient Compliance|Pneumonia, Viral|Program Evaluation|Prospective Studies|SARS-CoV-2|Specimen Handling|Time Factors|NA",Comparison of four COVID-19 screening strategies to facilitate early case identification within the homeless shelter population: A structured summary of a study protocol for a randomised controlled trial.,2020-11-26,Trials,https://pubmed.ncbi.nlm.nih.gov/33225995,https://clinicaltrials.gov/ct2/show/NCT04438070
33232588,NCT04383535,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.,2021-02-18,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33232588,https://clinicaltrials.gov/ct2/show/NCT04383535
33234158,NCT04529525,Abstract,Letter|Randomized Controlled Trial,Antiparasitic Agents|Placebos|Ivermectin|NA,Adult|Antiparasitic Agents|Argentina|COVID-19|Case-Control Studies|Double-Blind Method|Female|Hospitalization|Humans|Ivermectin|Male|Pandemics|Placebos|Prospective Studies|SARS-CoV-2|Time Factors|NA,Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.,2020-12-07,Trials,https://pubmed.ncbi.nlm.nih.gov/33234158,https://clinicaltrials.gov/ct2/show/NCT04529525
33234651,NCT04341142,Abstract,Clinical Study|Journal Article|Multicenter Study,"Antibodies, Viral|NA","Antibodies, Viral|COVID-19|Female|Humans|Male|Mass Screening|Pandemics|Prospective Studies|SARS-CoV-2|Serologic Tests|NA","Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study.",2020-12-10,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33234651,https://clinicaltrials.gov/ct2/show/NCT04341142
33239100,NCT04430608,Abstract,Letter|Randomized Controlled Trial, ,"Adult|Blood Glucose Self-Monitoring|COVID-19|Denmark|Diabetes Mellitus, Type 2|Female|Glycemic Control|Health Personnel|Hospitalization|Humans|Infectious Disease Transmission, Patient-to-Professional|Male|Quarantine|Remote Consultation|SARS-CoV-2|NA",Remote continuous glucose monitoring during the COVID-19 pandemic in quarantined hospitalized patients in Denmark: A structured summary of a study protocol for a randomized controlled trial.,2020-12-07,Trials,https://pubmed.ncbi.nlm.nih.gov/33239100,https://clinicaltrials.gov/ct2/show/NCT04430608
33240091,NCT04244591,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04244591
33240091,NCT04348695,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04348695
33240091,NCT04280705,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04280705
33240091,NCT04321174,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04321174
33240091,NCT04342663,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04342663
33240091,NCT04359329,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04359329
33240091,NCT04304313,Abstract,Journal Article|Review, , ,Challenges for Drug Repurposing in the COVID-19 Pandemic Era.,2020-11-27,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33240091,https://clinicaltrials.gov/ct2/show/NCT04304313
33246499,NCT04429854,Abstract,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial","Antibodies, Viral|NA","Adult|Antibodies, Viral|Belgium|COVID-19|Combined Modality Therapy|Female|Global Burden of Disease|Hospitalization|Humans|Immunization, Passive|Male|Mortality|Respiration, Artificial|SARS-CoV-2|Safety|Standard of Care|Treatment Outcome|NA","A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.",2020-12-07,Trials,https://pubmed.ncbi.nlm.nih.gov/33246499,https://clinicaltrials.gov/ct2/show/NCT04429854
33247380,NCT04447534,Abstract,Journal Article, , ,"Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial.",2020-12-02,Biological trace element research,https://pubmed.ncbi.nlm.nih.gov/33247380,https://clinicaltrials.gov/ct2/show/NCT04447534
33251500,NCT04349592,Abstract,Journal Article, , ,Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.,2020-12-18,EClinicalMedicine,https://pubmed.ncbi.nlm.nih.gov/33251500,https://clinicaltrials.gov/ct2/show/NCT04349592
33259326,NCT04445324,Abstract,Journal Article, , ,Online and Recovery-Oriented Support Groups Facilitated by Peer Support Workers in Times of COVID-19: Protocol for a Feasibility Pre-Post Study.,2020-12-31,JMIR research protocols,https://pubmed.ncbi.nlm.nih.gov/33259326,https://clinicaltrials.gov/ct2/show/NCT04445324
33264556,NCT04315948,Abstract,"Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|Lopinavir|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Alanine|Interferon beta-1a|NA,"Adenosine Monophosphate|Aged|Alanine|Antiviral Agents|COVID-19|Drug Therapy, Combination|Female|Hospital Mortality|Hospitalization|Humans|Hydroxychloroquine|Intention to Treat Analysis|Interferon beta-1a|Kaplan-Meier Estimate|Length of Stay|Lopinavir|Male|Middle Aged|Respiration, Artificial|Treatment Failure|NA",Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.,2021-02-12,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33264556,https://clinicaltrials.gov/ct2/show/NCT04315948
33267662,NCT04402970,Abstract,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04402970
33267662,NCT04402944,Abstract,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04402944
33267662,NCT04541979,Abstract,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04541979
33267662,NCT04432987,Abstract,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04432987
33267662,NCT04445285,Abstract,Journal Article, , ,Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.,2021-01-29,"Arteriosclerosis, thrombosis, and vascular biology",https://pubmed.ncbi.nlm.nih.gov/33267662,https://clinicaltrials.gov/ct2/show/NCT04445285
33270471,NCT04343053,Abstract,Journal Article, , ,"Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure.",2020-12-24,Platelets,https://pubmed.ncbi.nlm.nih.gov/33270471,https://clinicaltrials.gov/ct2/show/NCT04343053
33272319,NCT04395807,Abstract,Comparative Study|Journal Article|Randomized Controlled Trial, ,"Adult|COVID-19|Cannula|Continuous Positive Airway Pressure|Female|Head Protective Devices|Humans|Hypoxia|Male|Oxygen Inhalation Therapy|Positive-Pressure Respiration|Respiration, Artificial|SARS-CoV-2|Sweden|NA",Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET).,2020-12-14,Trials,https://pubmed.ncbi.nlm.nih.gov/33272319,https://clinicaltrials.gov/ct2/show/NCT04395807
33273742,NCT04405570,Abstract,"Journal Article|Research Support, N.I.H., Extramural",Antiviral Agents|Cytokines|Hydroxylamines|remdesivir|Adenosine Monophosphate|Cytidine|Alanine|molnupiravir|NA,"Adenosine Monophosphate|Alanine|Animals|Antiviral Agents|COVID-19|Chlorocebus aethiops|Cytidine|Cytokines|Disease Models, Animal|Disease Transmission, Infectious|Female|Ferrets|Hydroxylamines|Random Allocation|SARS-CoV-2|Vero Cells|NA",Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.,2021-01-13,Nature microbiology,https://pubmed.ncbi.nlm.nih.gov/33273742,https://clinicaltrials.gov/ct2/show/NCT04405570
33273742,NCT04405739,Abstract,"Journal Article|Research Support, N.I.H., Extramural",Antiviral Agents|Cytokines|Hydroxylamines|remdesivir|Adenosine Monophosphate|Cytidine|Alanine|molnupiravir|NA,"Adenosine Monophosphate|Alanine|Animals|Antiviral Agents|COVID-19|Chlorocebus aethiops|Cytidine|Cytokines|Disease Models, Animal|Disease Transmission, Infectious|Female|Ferrets|Hydroxylamines|Random Allocation|SARS-CoV-2|Vero Cells|NA",Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.,2021-01-13,Nature microbiology,https://pubmed.ncbi.nlm.nih.gov/33273742,https://clinicaltrials.gov/ct2/show/NCT04405739
33284679,NCT04328961,Abstract,Journal Article, , ,Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.,2021-01-22,Annals of internal medicine,https://pubmed.ncbi.nlm.nih.gov/33284679,https://clinicaltrials.gov/ct2/show/NCT04328961
33287790,NCT04558476,Abstract,Clinical Trial Protocol|Journal Article,"Antibodies, Viral|NA","Adult|Antibodies, Viral|Belgium|COVID-19|Clinical Trials, Phase II as Topic|Humans|Immunization, Passive|Intensive Care Units|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|Respiration, Artificial|Severe Acute Respiratory Syndrome|Time Factors|Treatment Outcome|NA",A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.,2020-12-21,BMC pulmonary medicine,https://pubmed.ncbi.nlm.nih.gov/33287790,https://clinicaltrials.gov/ct2/show/NCT04558476
33289973,NCT04304053,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anti-Infective Agents|Hydroxychloroquine|NA,"Adult|Anti-Infective Agents|COVID-19|Disease Transmission, Infectious|Double-Blind Method|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Patient Compliance|SARS-CoV-2|Treatment Failure|Viral Load|NA",A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.,2021-02-09,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33289973,https://clinicaltrials.gov/ct2/show/NCT04304053
33290245,NCT04476667,Abstract,Journal Article, , ,Using the Online Psychotherapy Tool to Address Mental Health Problems in the Context of the COVID-19 Pandemic: Protocol for an Electronically Delivered Cognitive Behavioral Therapy Program.,2020-12-31,JMIR research protocols,https://pubmed.ncbi.nlm.nih.gov/33290245,https://clinicaltrials.gov/ct2/show/NCT04476667
33298117,NCT04369378,Abstract,Letter|Randomized Controlled Trial, ,Adult|Anxiety|COVID-19|Case-Control Studies|Humans|Meditation|Mindfulness|Mobile Applications|SARS-CoV-2|Surveys and Questionnaires|NA,Effectiveness of using a meditation app in reducing anxiety and improving well-being during the COVID-19 pandemic: A structured summary of a study protocol for a randomized controlled trial.,2020-12-21,Trials,https://pubmed.ncbi.nlm.nih.gov/33298117,https://clinicaltrials.gov/ct2/show/NCT04369378
33301246,NCT04368728,Abstract,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","COVID-19 Vaccines|Vaccines, Synthetic|mRNA Vaccine|BNT162 vaccine|NA","Adolescent|Adult|Aged|COVID-19|COVID-19 Vaccines|Fatigue|Female|Headache|Humans|Immunization, Secondary|Male|Middle Aged|SARS-CoV-2|Single-Blind Method|Treatment Outcome|Vaccines, Synthetic|Young Adult|NA",Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.,2021-01-12,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33301246,https://clinicaltrials.gov/ct2/show/NCT04368728
33302976,NCT04362059,Abstract,Letter|Randomized Controlled Trial,Surface-Active Agents|NA,"Adult|COVID-19|Case-Control Studies|Feasibility Studies|Humans|Intensive Care Units|London|Mortality|Nebulizers and Vaporizers|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Safety|Surface-Active Agents|Treatment Outcome|Ventilation|NA",Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.,2020-12-21,Trials,https://pubmed.ncbi.nlm.nih.gov/33302976,https://clinicaltrials.gov/ct2/show/NCT04362059
33303470,NCT04348929,Abstract,Comparative Study|Journal Article|Multicenter Study, ,"COVID-19|Depression, Postpartum|Female|France|Humans|Parturition|Physical Distancing|Postpartum Period|Pregnancy|Prospective Studies|Psychiatric Status Rating Scales|Research Design|Stress Disorders, Post-Traumatic|Surveys and Questionnaires|Time Factors|NA",Birth experience during COVID-19 confinement (CONFINE): protocol for a multicentre prospective study.,2020-12-29,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33303470,https://clinicaltrials.gov/ct2/show/NCT04348929
33304914,NCT04351906,Abstract,Journal Article, , ,Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform to Enhance Lung-Protective Ventilation in Hypercapnic Patients With Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome.,2020-12-12,Frontiers in medicine,https://pubmed.ncbi.nlm.nih.gov/33304914,https://clinicaltrials.gov/ct2/show/NCT04351906
33306283,NCT04401579,Abstract,Journal Article, , ,Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.,2021-01-26,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33306283,https://clinicaltrials.gov/ct2/show/NCT04401579
33306989,NCT04324606,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,Adolescent|Adult|Aged|Brazil|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Male|Middle Aged|Single-Blind Method|South Africa|Treatment Outcome|United Kingdom|Young Adult|NA,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.",2021-02-01,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/33306989,https://clinicaltrials.gov/ct2/show/NCT04324606
33306989,NCT04444674,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,Adolescent|Adult|Aged|Brazil|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Male|Middle Aged|Single-Blind Method|South Africa|Treatment Outcome|United Kingdom|Young Adult|NA,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.",2021-02-01,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/33306989,https://clinicaltrials.gov/ct2/show/NCT04444674
33306989,NCT04400838,Abstract,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",COVID-19 Vaccines|ChAdOx1 COVID-19 vaccine|NA,Adolescent|Adult|Aged|Brazil|COVID-19|COVID-19 Vaccines|Double-Blind Method|Female|Humans|Male|Middle Aged|Single-Blind Method|South Africa|Treatment Outcome|United Kingdom|Young Adult|NA,"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.",2021-02-01,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/33306989,https://clinicaltrials.gov/ct2/show/NCT04400838
33307107,NCT04315480,Abstract,"Clinical Trial, Phase II|Journal Article|Multicenter Study","Antibodies, Monoclonal, Humanized|Biomarkers|Circulating MicroRNA|MIRN146 microRNA, human|MicroRNAs|tocilizumab|NA","Adult|Aged|Antibodies, Monoclonal, Humanized|Biomarkers|COVID-19|Circulating MicroRNA|Female|Humans|Inflammation|Male|MicroRNAs|Middle Aged|Pandemics|SARS-CoV-2|NA",Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.,2021-01-12,Mechanisms of ageing and development,https://pubmed.ncbi.nlm.nih.gov/33307107,https://clinicaltrials.gov/ct2/show/NCT04315480
33329103,NCT04555005,Abstract,Journal Article, , ,"Implementation of a Mindfulness-Based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain.",2020-12-18,Frontiers in psychiatry,https://pubmed.ncbi.nlm.nih.gov/33329103,https://clinicaltrials.gov/ct2/show/NCT04555005
33332778,NCT04425629,Abstract,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Drug Combinations|Immunologic Factors|REGN-COV-2|NA","Adult|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|COVID-19|Double-Blind Method|Drug Combinations|Female|Humans|Immunologic Factors|Least-Squares Analysis|Male|Middle Aged|Outpatients|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA","REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.",2021-02-03,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33332778,https://clinicaltrials.gov/ct2/show/NCT04425629
33332779,NCT04372186,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Antibodies, Monoclonal, Humanized|tocilizumab|NA","Adult|Aged|Antibodies, Monoclonal, Humanized|COVID-19|Disease Progression|Female|Hospitalization|Humans|Intention to Treat Analysis|Male|Middle Aged|Pneumonia, Viral|Respiration, Artificial|Survival Rate|NA",Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.,2021-01-12,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33332779,https://clinicaltrials.gov/ct2/show/NCT04372186
33335322,NCT04324606,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.,2021-02-17,Nature medicine,https://pubmed.ncbi.nlm.nih.gov/33335322,https://clinicaltrials.gov/ct2/show/NCT04324606
33335323,NCT04400838,Abstract,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't", , ,T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.,2021-02-17,Nature medicine,https://pubmed.ncbi.nlm.nih.gov/33335323,https://clinicaltrials.gov/ct2/show/NCT04400838
33347320,NCT04371419,Abstract,Journal Article, , ,Comparison of Knowledge and Information-Seeking Behavior After General COVID-19 Public Health Messages and Messages Tailored for Black and Latinx Communities : A Randomized Controlled Trial.,2021-01-05,Annals of internal medicine,https://pubmed.ncbi.nlm.nih.gov/33347320,https://clinicaltrials.gov/ct2/show/NCT04371419
33356051,NCT04501978,Abstract,Journal Article, , ,A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.,2021-02-03,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33356051,https://clinicaltrials.gov/ct2/show/NCT04501978
33371905,NCT04344041,Abstract,Journal Article|Multicenter Study|Randomized Controlled Trial,Vitamins|Vitamin D|NA,"Aged|COVID-19|Dietary Supplements|Dose-Response Relationship, Drug|Female|Humans|Male|Nutrition Therapy|Pandemics|Risk Factors|SARS-CoV-2|Time Factors|Treatment Outcome|Vitamin D|Vitamins|NA",COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial.,2021-01-06,Trials,https://pubmed.ncbi.nlm.nih.gov/33371905,https://clinicaltrials.gov/ct2/show/NCT04344041
33377218,NCT04635241,Abstract,Journal Article, , ,INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies.,2021-01-19,British journal of clinical pharmacology,https://pubmed.ncbi.nlm.nih.gov/33377218,https://clinicaltrials.gov/ct2/show/NCT04635241
33378609,NCT04470427,Abstract,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't","COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|mRNA-1273 vaccine|NA","Adolescent|Adult|Aged|COVID-19|COVID-19 Vaccines|Female|Humans|Incidence|Male|Middle Aged|Patient Acuity|SARS-CoV-2|Single-Blind Method|Spike Glycoprotein, Coronavirus|Treatment Outcome|Young Adult|NA",Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.,2021-02-09,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33378609,https://clinicaltrials.gov/ct2/show/NCT04470427
33392485,NCT04336410,Abstract,Journal Article, , ,"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.",2021-01-30,EClinicalMedicine,https://pubmed.ncbi.nlm.nih.gov/33392485,https://clinicaltrials.gov/ct2/show/NCT04336410
33397432,NCT04549376,Abstract,Clinical Trial Protocol|Letter,"Anti-Infective Agents, Local|Nasal Sprays|Placebos|Povidone-Iodine|NA","Administration, Intranasal|Adolescent|Adult|Aged|Aged, 80 and over|Anti-Infective Agents, Local|Bangladesh|COVID-19|Clinical Trials, Phase II as Topic|Dose-Response Relationship, Drug|Female|Humans|Male|Middle Aged|Nasal Lavage|Nasal Sprays|Nasopharynx|Placebos|Povidone-Iodine|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|Young Adult|NA",Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.,2021-01-12,Trials,https://pubmed.ncbi.nlm.nih.gov/33397432,https://clinicaltrials.gov/ct2/show/NCT04549376
33397449,NCT04414631,Abstract,Clinical Trial Protocol|Letter,Complement C1 Inhibitor Protein|Recombinant Proteins|constat alfa|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Brazil|COVID-19|Clinical Trials, Phase II as Topic|Complement C1 Inhibitor Protein|Drug Administration Schedule|Female|Humans|Injections, Intravenous|Male|Mexico|Middle Aged|Multicenter Studies as Topic|Pilot Projects|Randomized Controlled Trials as Topic|Recombinant Proteins|SARS-CoV-2|Severity of Illness Index|Switzerland|Treatment Outcome|Young Adult|NA","Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).",2021-01-12,Trials,https://pubmed.ncbi.nlm.nih.gov/33397449,https://clinicaltrials.gov/ct2/show/NCT04414631
33397457,NCT04459286,Abstract,Clinical Trial Protocol|Comparative Study|Letter,"Antiviral Agents|Drug Combinations|RNA, Viral|Thiazoles|Atazanavir Sulfate|Ritonavir|nitazoxanide|NA","Administration, Oral|Adolescent|Adult|Aged|Antiviral Agents|Atazanavir Sulfate|COVID-19|COVID-19 Nucleic Acid Testing|Clinical Trials, Phase II as Topic|Drug Administration Schedule|Drug Combinations|Drug Repositioning|Drug Therapy, Combination|Female|Humans|Male|Middle Aged|Multicenter Studies as Topic|Nigeria|Pilot Projects|RNA, Viral|Randomized Controlled Trials as Topic|Ritonavir|SARS-CoV-2|Severity of Illness Index|Standard of Care|Thiazoles|Treatment Outcome|Viral Load|Young Adult|NA",Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.,2021-01-12,Trials,https://pubmed.ncbi.nlm.nih.gov/33397457,https://clinicaltrials.gov/ct2/show/NCT04459286
33406353,NCT04479163,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.,2021-02-18,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33406353,https://clinicaltrials.gov/ct2/show/NCT04479163
33407777,NCT04615429,Abstract,Clinical Trial Protocol|Letter,Antiviral Agents|Biomarkers|NA,"Administration, Intravenous|Adult|Antiviral Agents|Biomarkers|COVID-19|Clinical Trials, Phase II as Topic|Combined Modality Therapy|Double-Blind Method|Female|Humans|Male|Mesenchymal Stem Cell Transplantation|Randomized Controlled Trials as Topic|Respiration, Artificial|Respiratory Distress Syndrome|SARS-CoV-2|Severity of Illness Index|Spain|Standard of Care|Transplantation, Homologous|NA","Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.",2021-01-12,Trials,https://pubmed.ncbi.nlm.nih.gov/33407777,https://clinicaltrials.gov/ct2/show/NCT04615429
33422263,NCT04338009,Abstract,Journal Article, , ,"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.",2021-01-27,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/33422263,https://clinicaltrials.gov/ct2/show/NCT04338009
33429174,NCT04484493,Abstract,Journal Article, , ,Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.,2021-02-07,American journal of otolaryngology,https://pubmed.ncbi.nlm.nih.gov/33429174,https://clinicaltrials.gov/ct2/show/NCT04484493
33430891,NCT04438980,Abstract,Clinical Trial Protocol|Letter,Glucocorticoids|Interleukin-6|C-Reactive Protein|Ferritins|Methylprednisolone|NA,"C-Reactive Protein|COVID-19|Double-Blind Method|Ferritins|Glucocorticoids|Hospitalization|Humans|Infusions, Intravenous|Interleukin-6|Methylprednisolone|Pulse Therapy, Drug|Randomized Controlled Trials as Topic|SARS-CoV-2|Treatment Outcome|NA",Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.,2021-01-18,Trials,https://pubmed.ncbi.nlm.nih.gov/33430891,https://clinicaltrials.gov/ct2/show/NCT04438980
33430924,NCT04472728,Abstract,Clinical Trial Protocol|Letter,"Proto-Oncogene Proteins|Receptors, Coronavirus|Receptors, G-Protein-Coupled|Spike Glycoprotein, Coronavirus|proto-oncogene proteins c-mas-1|spike protein, SARS-CoV-2|Ecdysterone|Angiotensin-Converting Enzyme 2|NA","Aged|Aged, 80 and over|Angiotensin-Converting Enzyme 2|COVID-19|Disease Progression|Double-Blind Method|Ecdysterone|Extracorporeal Membrane Oxygenation|Hospitalization|Humans|Hypoxia|Middle Aged|Mortality|Oxygen Inhalation Therapy|Proto-Oncogene Proteins|Randomized Controlled Trials as Topic|Receptors, Coronavirus|Receptors, G-Protein-Coupled|Renin-Angiotensin System|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Tachypnea|Treatment Outcome|NA","Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.",2021-01-18,Trials,https://pubmed.ncbi.nlm.nih.gov/33430924,https://clinicaltrials.gov/ct2/show/NCT04472728
33440088,NCT04436276,Abstract,Journal Article, , ,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.,2021-01-30,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33440088,https://clinicaltrials.gov/ct2/show/NCT04436276
33446655,NCT04368988,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|COVID-19 Vaccines|Spike Glycoprotein, Coronavirus|Vaccines, Subunit|spike glycoprotein, SARS-CoV|Angiotensin-Converting Enzyme 2|NA","Angiotensin-Converting Enzyme 2|Animals|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|COVID-19 Vaccines|Disease Models, Animal|Female|Humans|Male|Mice|Mice, Inbred BALB C|Papio|SARS-CoV-2|Spike Glycoprotein, Coronavirus|T-Lymphocytes|Vaccines, Subunit|NA",SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.,2021-01-19,Nature communications,https://pubmed.ncbi.nlm.nih.gov/33446655,https://clinicaltrials.gov/ct2/show/NCT04368988
33455938,NCT04385771,Abstract,Clinical Trial Protocol|Journal Article,Cytokines|Interleukin-6|NA,COVID-19|Cytokines|Extracorporeal Membrane Oxygenation|Germany|Humans|Interleukin-6|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|Severity of Illness Index|Time Factors|Treatment Outcome|NA,"Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial.",2021-02-01,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33455938,https://clinicaltrials.gov/ct2/show/NCT04385771
33464336,NCT04364893,Abstract,Journal Article|Multicenter Study|Pragmatic Clinical Trial|Randomized Controlled Trial,Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|NA,"Aged|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|COVID-19|Disease Progression|Female|Heart Failure|Hospitalization|Humans|Male|Middle Aged|Myocardial Infarction|Odds Ratio|Patient Discharge|Respiration, Artificial|Respiratory Insufficiency|SARS-CoV-2|Sample Size|Shock|Time Factors|Treatment Outcome|Withholding Treatment|NA",Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.,2021-01-27,JAMA,https://pubmed.ncbi.nlm.nih.gov/33464336,https://clinicaltrials.gov/ct2/show/NCT04364893
33472681,NCT04345523,Abstract,Clinical Trial Protocol|Journal Article, ,"Adult|COVID-19|Clinical Trials, Phase II as Topic|Female|Hospitalization|Humans|Immunization, Passive|Male|Middle Aged|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|SARS-CoV-2|Severity of Illness Index|Standard of Care|Treatment Outcome|NA","Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.",2021-01-26,Trials,https://pubmed.ncbi.nlm.nih.gov/33472681,https://clinicaltrials.gov/ct2/show/NCT04345523
33472855,NCT04403685,Abstract,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't","Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|tocilizumab|NA","Adolescent|Adult|Aged|Aged, 80 and over|Anti-Inflammatory Agents|Antibodies, Monoclonal, Humanized|COVID-19|Critical Illness|Female|Follow-Up Studies|Hospitalization|Humans|Infusions, Intravenous|Male|Middle Aged|Respiration, Artificial|Severity of Illness Index|Treatment Outcome|Young Adult|NA",Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.,2021-01-27,BMJ (Clinical research ed.),https://pubmed.ncbi.nlm.nih.gov/33472855,https://clinicaltrials.gov/ct2/show/NCT04403685
33475701,NCT04427501,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.,2021-02-18,JAMA,https://pubmed.ncbi.nlm.nih.gov/33475701,https://clinicaltrials.gov/ct2/show/NCT04427501
33482902,NCT04319731,Abstract,Clinical Trial|Journal Article,Biomarkers|Inflammation Mediators|NA,Adult|Aged|Amniotic Fluid|Biomarkers|COVID-19|Female|Hospital Mortality|Humans|Inflammation Mediators|Male|Middle Aged|Pilot Projects|Pregnancy|Time Factors|Treatment Outcome|Young Adult|NA,A pilot trial of human amniotic fluid for the treatment of COVID-19.,2021-01-27,BMC research notes,https://pubmed.ncbi.nlm.nih.gov/33482902,https://clinicaltrials.gov/ct2/show/NCT04319731
33485468,NCT04471519,Abstract,Journal Article, , ,"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.",2021-01-29,The Lancet. Infectious diseases,https://pubmed.ncbi.nlm.nih.gov/33485468,https://clinicaltrials.gov/ct2/show/NCT04471519
33486496,NCT04273321,Abstract,Journal Article, , ,"Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial.",2021-01-24,Respiration; international review of thoracic diseases,https://pubmed.ncbi.nlm.nih.gov/33486496,https://clinicaltrials.gov/ct2/show/NCT04273321
33492523,NCT04351295,Abstract,Journal Article, , ,Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.,2021-02-16,Archives of virology,https://pubmed.ncbi.nlm.nih.gov/33492523,https://clinicaltrials.gov/ct2/show/NCT04351295
33495742,NCT04341038,Abstract,Journal Article|Review, , ,"Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.",2021-01-27,Contemporary clinical trials communications,https://pubmed.ncbi.nlm.nih.gov/33495742,https://clinicaltrials.gov/ct2/show/NCT04341038
33495752,NCT04390022,Abstract,Journal Article, , ,"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.",2021-01-27,EClinicalMedicine,https://pubmed.ncbi.nlm.nih.gov/33495752,https://clinicaltrials.gov/ct2/show/NCT04390022
33499887,NCT04451174,Abstract,Letter,"RNA, Viral|NA","COVID-19|Critical Care|Hospitalization|Humans|RNA, Viral|Randomized Controlled Trials as Topic|Respiration, Artificial|SARS-CoV-2|Treatment Outcome|NA",Early use of corticosteroids in non-critical patients with COVID-19 pneumonia (PREDCOVID): a structured summary of a study protocol for a randomised controlled trial.,2021-02-03,Trials,https://pubmed.ncbi.nlm.nih.gov/33499887,https://clinicaltrials.gov/ct2/show/NCT04451174
33502567,NCT04394182,Abstract,Journal Article, , ,COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): aÂ single institution report of two cases.,2021-01-30,Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],https://pubmed.ncbi.nlm.nih.gov/33502567,https://clinicaltrials.gov/ct2/show/NCT04394182
33502773,NCT04373707,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04373707
33502773,NCT04354155,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04354155
33502773,NCT04345848,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04345848
33502773,NCT04359277,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04359277
33502773,NCT04368377,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04368377
33502773,NCT04362085,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04362085
33502773,NCT04367831,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04367831
33502773,NCT04360824,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04360824
33502773,NCT04394377,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04394377
33502773,NCT04401293,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04401293
33502773,NCT04397510,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04397510
33502773,NCT04372589,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04372589
33502773,NCT04366960,Abstract,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review",Anticoagulants|NA,Aged|Anticoagulants|Bias|COVID-19|Cause of Death|Hemorrhage|Hospitalization|Humans|Middle Aged|Retrospective Studies|SARS-CoV-2|Thromboembolism|NA,Prophylactic anticoagulants for people hospitalised with COVID-19.,2021-02-03,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/33502773,https://clinicaltrials.gov/ct2/show/NCT04366960
33505321,NCT04647604,Abstract,Journal Article|Review, , ,Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the <i>COVID-Omega-F</i> Trial.,2021-01-30,Frontiers in physiology,https://pubmed.ncbi.nlm.nih.gov/33505321,https://clinicaltrials.gov/ct2/show/NCT04647604
33519339,NCT04347681,Abstract,Journal Article, , ,Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.,2021-02-02,Saudi journal of medicine &amp; medical sciences,https://pubmed.ncbi.nlm.nih.gov/33519339,https://clinicaltrials.gov/ct2/show/NCT04347681
33522946,NCT04411446,Abstract,Clinical Trial Protocol|Letter,Vitamins|Cholecalciferol|NA,"Aged|Aged, 80 and over|Argentina|COVID-19|Cholecalciferol|Double-Blind Method|Female|Humans|Male|Middle Aged|Multicenter Studies as Topic|Pandemics|Patient Admission|Pragmatic Clinical Trials as Topic|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Treatment Outcome|Vitamins|NA",High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).,2021-02-19,Trials,https://pubmed.ncbi.nlm.nih.gov/33522946,https://clinicaltrials.gov/ct2/show/NCT04411446
33524311,NCT04405908,Abstract,Journal Article, , ,"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.",2021-02-01,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/33524311,https://clinicaltrials.gov/ct2/show/NCT04405908
33524990,NCT04368728,Abstract,Journal Article, , ,Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2.,2021-02-01,Nature,https://pubmed.ncbi.nlm.nih.gov/33524990,https://clinicaltrials.gov/ct2/show/NCT04368728
33524990,NCT04380701,Abstract,Journal Article, , ,Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2.,2021-02-01,Nature,https://pubmed.ncbi.nlm.nih.gov/33524990,https://clinicaltrials.gov/ct2/show/NCT04380701
33545094,NCT04530396,Abstract,Journal Article, , ,Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.,2021-02-19,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/33545094,https://clinicaltrials.gov/ct2/show/NCT04530396
33547300,NCT04275414,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,Efficacy and tolerability of bevacizumab in patients with severe Covid-19.,2021-02-17,Nature communications,https://pubmed.ncbi.nlm.nih.gov/33547300,https://clinicaltrials.gov/ct2/show/NCT04275414
33548194,NCT04383574,Abstract,Journal Article, , ,"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.",2021-02-06,The Lancet. Infectious diseases,https://pubmed.ncbi.nlm.nih.gov/33548194,https://clinicaltrials.gov/ct2/show/NCT04383574
33556319,NCT04354259,Abstract,Journal Article, , ,"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.",2021-02-08,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/33556319,https://clinicaltrials.gov/ct2/show/NCT04354259
33557591,NCT04521309,Abstract,"Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Viral|Caprylates|Immunoglobulins, Intravenous|NA","Antibodies, Viral|COVID-19|Caprylates|Chemical Fractionation|Humans|Immunization, Passive|Immunoglobulins, Intravenous|SARS-CoV-2|NA",Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.,2021-02-18,Immunotherapy,https://pubmed.ncbi.nlm.nih.gov/33557591,https://clinicaltrials.gov/ct2/show/NCT04521309
33562419,NCT04568525,Abstract,Journal Article, , ,Passive Microwave Radiometry for the Diagnosis of Coronavirus Disease 2019 Lung Complications in Kyrgyzstan.,2021-02-10,"Diagnostics (Basel, Switzerland)",https://pubmed.ncbi.nlm.nih.gov/33562419,https://clinicaltrials.gov/ct2/show/NCT04568525
33568226,NCT04473261,Abstract,Clinical Trial Protocol|Letter,Capsules|Iodine Compounds|Oral Sprays|Polymers|NA,Adult|COVID-19|Capsules|Female|Humans|Iodine Compounds|Male|Oral Sprays|Pakistan|Patient Admission|Polymers|Randomized Controlled Trials as Topic|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|NA,A quadruple blinded placebo controlled randomised trial to evaluate the effectiveness of an Iodine complex for patients with mild to moderate COVID-19 in Pakistan (I-COVID-PK): A structured summary of a study protocol for a randomised controlled trial.,2021-02-19,Trials,https://pubmed.ncbi.nlm.nih.gov/33568226,https://clinicaltrials.gov/ct2/show/NCT04473261
33568628,NCT04288102,Abstract,"Journal Article|Research Support, Non-U.S. Gov't", , ,"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.",2021-02-15,Signal transduction and targeted therapy,https://pubmed.ncbi.nlm.nih.gov/33568628,https://clinicaltrials.gov/ct2/show/NCT04288102
33570583,NCT04318444,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04318444
33570583,NCT04312243,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04312243
33570583,NCT04251871,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04251871
33570583,NCT04321174,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04321174
33570583,NCT04308668,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04308668
33570583,NCT04303507,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04303507
33570583,NCT04304053,Abstract,Journal Article, , ,Nutritional perspectives for the prevention and mitigation of COVID-19.,2021-02-16,Nutrition reviews,https://pubmed.ncbi.nlm.nih.gov/33570583,https://clinicaltrials.gov/ct2/show/NCT04304053
33571450,NCT04413968,Abstract,Journal Article, , ,"SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study.",2021-02-11,The Lancet. Child &amp; adolescent health,https://pubmed.ncbi.nlm.nih.gov/33571450,https://clinicaltrials.gov/ct2/show/NCT04413968
33573681,NCT04609865,Abstract,Clinical Trial Protocol|Letter,Voltage-Gated Sodium Channel Blockers|Lidocaine|NA,"Administration, Intravenous|COVID-19|Clinical Trials, Phase III as Topic|Equivalence Trials as Topic|Humans|Inflammation|Lidocaine|Pulmonary Gas Exchange|Randomized Controlled Trials as Topic|Respiratory Distress Syndrome|SARS-CoV-2|Treatment Outcome|Voltage-Gated Sodium Channel Blockers|NA",Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.,2021-02-18,Trials,https://pubmed.ncbi.nlm.nih.gov/33573681,https://clinicaltrials.gov/ct2/show/NCT04609865
33574155,NCT04497389,Abstract,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't", , ,"Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial.",2021-02-16,BMJ open,https://pubmed.ncbi.nlm.nih.gov/33574155,https://clinicaltrials.gov/ct2/show/NCT04497389
33576820,NCT04342728,Abstract,Journal Article, , ,Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.,2021-02-17,JAMA network open,https://pubmed.ncbi.nlm.nih.gov/33576820,https://clinicaltrials.gov/ct2/show/NCT04342728
33585031,NCT04730323,Abstract,Journal Article, , ,"&quot;Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience&quot;, a retrospective study-original article.",2021-02-16,Annals of medicine and surgery (2012),https://pubmed.ncbi.nlm.nih.gov/33585031,https://clinicaltrials.gov/ct2/show/NCT04730323
33595634,NCT04449718,Abstract,Journal Article, , ,Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.,2021-02-17,JAMA,https://pubmed.ncbi.nlm.nih.gov/33595634,https://clinicaltrials.gov/ct2/show/NCT04449718
29264361,NCT04466670,Registry,Journal Article|Review, , ,Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.,2020-10-01,Annals of translational medicine,https://pubmed.ncbi.nlm.nih.gov/29264361,https://clinicaltrials.gov/ct2/show/NCT04466670
29619244,NCT04333550,Registry,Journal Article, , ,Antiviral effects of ferric ammonium citrate.,2020-09-29,Cell discovery,https://pubmed.ncbi.nlm.nih.gov/29619244,https://clinicaltrials.gov/ct2/show/NCT04333550
29772761,NCT04382768,Registry,Journal Article, , ,High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens.,2020-10-01,"Pharmaceuticals (Basel, Switzerland)",https://pubmed.ncbi.nlm.nih.gov/29772761,https://clinicaltrials.gov/ct2/show/NCT04382768
30206520,NCT04468893,Registry,Journal Article, , ,The acceptability of an online intervention using positive psychology for depression: A qualitative study.,2020-09-30,Internet interventions,https://pubmed.ncbi.nlm.nih.gov/30206520,https://clinicaltrials.gov/ct2/show/NCT04468893
30505605,NCT04424953,Registry,Journal Article, , ,Haemodynamic Response to Four Different Laryngoscopes.,2020-10-01,Turkish journal of anaesthesiology and reanimation,https://pubmed.ncbi.nlm.nih.gov/30505605,https://clinicaltrials.gov/ct2/show/NCT04424953
30958989,NCT04482634,Registry,Journal Article|Review, , ,Optimizing Post-Intensive Care Unit Rehabilitation.,2020-09-28,Turkish thoracic journal,https://pubmed.ncbi.nlm.nih.gov/30958989,https://clinicaltrials.gov/ct2/show/NCT04482634
30976418,NCT04359095,Registry,Journal Article, , ,Clinical characteristics and outcomes of patients with severe acute respiratory infections (SARI): results from the Egyptian surveillance study 2010-2014.,2020-09-30,Multidisciplinary respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/30976418,https://clinicaltrials.gov/ct2/show/NCT04359095
31282542,NCT04410328,Registry,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural",Biomarkers|Phosphodiesterase Inhibitors|Dipyridamole|NA,Adolescent|Adult|Biomarkers|Chronic Disease|Dipyridamole|Double-Blind Method|HIV Infections|HIV-1|Humans|Inflammation|Middle Aged|Phosphodiesterase Inhibitors|Pilot Projects|Young Adult|NA,"A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.",2021-02-05,The Journal of infectious diseases,https://pubmed.ncbi.nlm.nih.gov/31282542,https://clinicaltrials.gov/ct2/show/NCT04410328
31346914,NCT04338568,Registry,Journal Article, , ,The diagnostic accuracy for ARDS of global versus regional lung ultrasound scores - a post hoc analysis of an observational study in invasively ventilated ICU patients.,2020-09-30,Intensive care medicine experimental,https://pubmed.ncbi.nlm.nih.gov/31346914,https://clinicaltrials.gov/ct2/show/NCT04338568
31606437,NCT04642326,Registry,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Canada|Disease Transmission, Infectious|Female|Graft Survival|Hepacivirus|Hepatitis C|Humans|Lung|Lung Transplantation|Male|Middle Aged|Perfusion|Pilot Projects|Proof of Concept Study|Prospective Studies|Tissue Donors|Transplants|Treatment Outcome|Viremia|NA","Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.",2020-08-24,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/31606437,https://clinicaltrials.gov/ct2/show/NCT04642326
31682582,NCT04374786,Registry,Journal Article, ,"Adolescent|Aged|Aged, 80 and over|Arizona|Cross-Sectional Studies|Female|Humans|Male|Meditation|Middle Aged|Mobile Applications|Patients|Surveys and Questionnaires|NA","Characteristics and Usage Patterns Among 12,151 Paid Subscribers of the Calm Meditation App: Cross-Sectional Survey.",2020-09-15,JMIR mHealth and uHealth,https://pubmed.ncbi.nlm.nih.gov/31682582,https://clinicaltrials.gov/ct2/show/NCT04374786
31762329,NCT04282902,Registry,Journal Article,Indoles|Pyridones|Bleomycin|pirfenidone|nintedanib|NA,"Animals|Bleomycin|Disease Models, Animal|Extracellular Matrix|Female|Idiopathic Pulmonary Fibrosis|Indoles|Lung|Myofibroblasts|Pyridones|Sheep|NA",The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.,2020-05-26,Experimental lung research,https://pubmed.ncbi.nlm.nih.gov/31762329,https://clinicaltrials.gov/ct2/show/NCT04282902
31818628,NCT04673214,Registry,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Anticoagulants|Fibrinolytic Agents|Rivaroxaban|NA,Anticoagulants|Colorectal Neoplasms|Fibrinolytic Agents|Humans|Laparoscopy|Rivaroxaban|Venous Thromboembolism|NA,Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY.,2021-02-15,European journal of internal medicine,https://pubmed.ncbi.nlm.nih.gov/31818628,https://clinicaltrials.gov/ct2/show/NCT04673214
31930543,NCT04642326,Registry,Journal Article,Methylene Blue|NA,"Blood Platelets|Blood Transfusion|Hemorrhagic Fever Virus, Crimean-Congo|Humans|Light|Methylene Blue|Nipah Virus|Plasma|SARS Virus|Ultraviolet Rays|Virus Inactivation|NA","Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light.",2020-10-19,Vox sanguinis,https://pubmed.ncbi.nlm.nih.gov/31930543,https://clinicaltrials.gov/ct2/show/NCT04642326
31933547,NCT04394182,Registry,Journal Article, , ,Application of Low Doses of Ionizing Radiation in Medical Therapies.,2020-09-30,Dose-response : a publication of International Hormesis Society,https://pubmed.ncbi.nlm.nih.gov/31933547,https://clinicaltrials.gov/ct2/show/NCT04394182
31936284,NCT04501965,Registry,Journal Article|Review, , ,The Use of Antimalarial Drugs against Viral Infection.,2020-09-30,Microorganisms,https://pubmed.ncbi.nlm.nih.gov/31936284,https://clinicaltrials.gov/ct2/show/NCT04501965
32031570,NCT04442178,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Disease Transmission, Infectious|Female|Hospitalization|Humans|Lung|Male|Middle Aged|Pandemics|Pneumonia, Viral|Real-Time Polymerase Chain Reaction|Retrospective Studies|SARS-CoV-2|Tomography, X-Ray Computed|Vital Signs|Young Adult|NA","Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.",2020-09-22,JAMA,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04442178
32031570,NCT04407689,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Disease Transmission, Infectious|Female|Hospitalization|Humans|Lung|Male|Middle Aged|Pandemics|Pneumonia, Viral|Real-Time Polymerase Chain Reaction|Retrospective Studies|SARS-CoV-2|Tomography, X-Ray Computed|Vital Signs|Young Adult|NA","Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.",2020-09-22,JAMA,https://pubmed.ncbi.nlm.nih.gov/32031570,https://clinicaltrials.gov/ct2/show/NCT04407689
32039812,NCT04374786,Registry,Journal Article, , ,Cancer Patients' and Survivors' Perceptions of the Calm App: Cross-Sectional Descriptive Study.,2020-09-28,JMIR cancer,https://pubmed.ncbi.nlm.nih.gov/32039812,https://clinicaltrials.gov/ct2/show/NCT04374786
32043986,NCT04325061,Registry,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Glucocorticoids|Dexamethasone|NA,"Administration, Intravenous|Adult|Aged|Dexamethasone|Female|Glucocorticoids|Humans|Intensive Care Units|Male|Middle Aged|Respiration, Artificial|Respiratory Distress Syndrome|Severity of Illness Index|Treatment Outcome|NA","Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.",2020-09-30,The Lancet. Respiratory medicine,https://pubmed.ncbi.nlm.nih.gov/32043986,https://clinicaltrials.gov/ct2/show/NCT04325061
32091533,NCT04353674,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|China|Communicable Disease Control|Coronavirus Infections|Disease Outbreaks|Humans|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|World Health Organization|NA",Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72â€¯314 Cases From the Chinese Center for Disease Control and Prevention.,2020-09-22,JAMA,https://pubmed.ncbi.nlm.nih.gov/32091533,https://clinicaltrials.gov/ct2/show/NCT04353674
32091533,NCT04366232,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Betacoronavirus|COVID-19|China|Communicable Disease Control|Coronavirus Infections|Disease Outbreaks|Humans|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|World Health Organization|NA",Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72â€¯314 Cases From the Chinese Center for Disease Control and Prevention.,2020-09-22,JAMA,https://pubmed.ncbi.nlm.nih.gov/32091533,https://clinicaltrials.gov/ct2/show/NCT04366232
32102726,NCT04424953,Registry,Journal Article, , ,Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease 2019.,2020-07-21,Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,https://pubmed.ncbi.nlm.nih.gov/32102726,https://clinicaltrials.gov/ct2/show/NCT04424953
32107577,NCT04627467,Registry,Journal Article, ,"Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|COVID-19 Testing|China|Clinical Laboratory Techniques|Coronavirus Infections|Cough|Disease Progression|Female|Fever|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Tomography, X-Ray Computed|Young Adult|NA",Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2.,2020-04-03,European journal of nuclear medicine and molecular imaging,https://pubmed.ncbi.nlm.nih.gov/32107577,https://clinicaltrials.gov/ct2/show/NCT04627467
32125452,NCT04353674,Registry,Letter, ,"Betacoronavirus|COVID-19|China|Coronavirus Infections|Female|Humans|Male|Pandemics|Pneumonia, Viral|Risk Assessment|Risk Factors|SARS-CoV-2|NA","Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.",2020-05-14,Intensive care medicine,https://pubmed.ncbi.nlm.nih.gov/32125452,https://clinicaltrials.gov/ct2/show/NCT04353674
32125458,NCT04344951,Registry,Journal Article, ,"COVID-19|Capacity Building|Coronavirus Infections|Health Personnel|Hospital Bed Capacity|Humans|Intensive Care Units|Pandemics|Personal Protective Equipment|Pneumonia, Viral|Surge Capacity|NA",COVID-19: a novel coronavirus and a novel challenge for critical care.,2020-05-14,Intensive care medicine,https://pubmed.ncbi.nlm.nih.gov/32125458,https://clinicaltrials.gov/ct2/show/NCT04344951
32129478,NCT04385043,Registry,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural","Antibodies, Neutralizing|Antibodies, Viral|Ficusin|NA","Animals|Antibodies, Neutralizing|Antibodies, Viral|Blood Donors|Chlorocebus aethiops|Convalescence|Ebolavirus|Ficusin|Hemorrhagic Fever, Ebola|Humans|Immunity, Active|Immunization, Passive|Neutralization Tests|Plasma|Seroconversion|United States|Vero Cells|Viral Load|NA",Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.,2020-09-08,Transfusion,https://pubmed.ncbi.nlm.nih.gov/32129478,https://clinicaltrials.gov/ct2/show/NCT04385043
32140081,NCT04394182,Registry,Journal Article|Review, , ,Low-Dose radiation therapy for benign pathologies.,2020-09-28,Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology,https://pubmed.ncbi.nlm.nih.gov/32140081,https://clinicaltrials.gov/ct2/show/NCT04394182
32150618,NCT04627467,Registry,"Journal Article|Research Support, Non-U.S. Gov't",Antiviral Agents|Hydroxychloroquine|Chloroquine|NA,"Animals|Antiviral Agents|Betacoronavirus|COVID-19|Cell Line|Chlorocebus aethiops|Chloroquine|Coronavirus Infections|Hydroxychloroquine|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|Severe Acute Respiratory Syndrome|Vero Cells|NA",In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).,2020-08-10,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,https://pubmed.ncbi.nlm.nih.gov/32150618,https://clinicaltrials.gov/ct2/show/NCT04627467
32159775,NCT04517162,Registry,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't","RNA, Viral|NA","Adolescent|Adult|Aged|Betacoronavirus|Bronchoalveolar Lavage Fluid|Bronchoscopy|COVID-19|Child|Child, Preschool|China|Coronavirus Infections|Feces|Female|Gene Dosage|Genes, Viral|Humans|Male|Middle Aged|Nose|Open Reading Frames|Pandemics|Pharynx|Pneumonia, Viral|RNA, Viral|Real-Time Polymerase Chain Reaction|SARS-CoV-2|Sputum|Viral Load|Young Adult|NA",Detection of SARS-CoV-2 in Different Types of Clinical Specimens.,2020-09-23,JAMA,https://pubmed.ncbi.nlm.nih.gov/32159775,https://clinicaltrials.gov/ct2/show/NCT04517162
32167524,NCT04494724,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Age Factors|Aged|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Female|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Patient Care Planning|Pneumonia, Viral|Respiratory Distress Syndrome|Retrospective Studies|SARS-CoV-2|NA","Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.",2020-09-30,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04494724
32167524,NCT04353674,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Age Factors|Aged|Betacoronavirus|COVID-19|China|Coronavirus Infections|Critical Illness|Female|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Patient Care Planning|Pneumonia, Viral|Respiratory Distress Syndrome|Retrospective Studies|SARS-CoV-2|NA","Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.",2020-09-30,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/32167524,https://clinicaltrials.gov/ct2/show/NCT04353674
32171076,NCT04479202,Registry,Journal Article,Fibrin Fibrinogen Degradation Products|fibrin fragment D|NA,"Adolescent|Adult|Age Factors|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|COVID-19 Testing|Cardiovascular Diseases|China|Clinical Laboratory Techniques|Cohort Studies|Comorbidity|Coronavirus Infections|Diabetes Complications|Disease Progression|Female|Fibrin Fibrinogen Degradation Products|Humans|Hypertension|Male|Middle Aged|Mortality|Organ Dysfunction Scores|Pandemics|Patient Care Planning|Patient Isolation|Pneumonia, Viral|Prognosis|Retrospective Studies|Risk Assessment|Risk Factors|SARS-CoV-2|Young Adult|NA","Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.",2020-04-03,"Lancet (London, England)",https://pubmed.ncbi.nlm.nih.gov/32171076,https://clinicaltrials.gov/ct2/show/NCT04479202
32171740,NCT04340349,Registry,Journal Article,Antiviral Agents|Chloroquine|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Drug Evaluation, Preclinical|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,2020-05-28,International journal of antimicrobial agents,https://pubmed.ncbi.nlm.nih.gov/32171740,https://clinicaltrials.gov/ct2/show/NCT04340349
32171740,NCT04344951,Registry,Journal Article,Antiviral Agents|Chloroquine|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Drug Evaluation, Preclinical|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,2020-05-28,International journal of antimicrobial agents,https://pubmed.ncbi.nlm.nih.gov/32171740,https://clinicaltrials.gov/ct2/show/NCT04344951
32173110,NCT04384380,Registry,Journal Article|Systematic Review,Antimalarials|Chloroquine|NA,"Antimalarials|Betacoronavirus|COVID-19|China|Chloroquine|Clinical Trials as Topic|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|World Health Organization|NA",A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.,2020-05-22,Journal of critical care,https://pubmed.ncbi.nlm.nih.gov/32173110,https://clinicaltrials.gov/ct2/show/NCT04384380
32179124,NCT04627467,Registry,Journal Article|Meta-Analysis|Systematic Review, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Cough|Fever|Hospitalization|Humans|Intensive Care Units|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA","Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.",2020-05-18,Travel medicine and infectious disease,https://pubmed.ncbi.nlm.nih.gov/32179124,https://clinicaltrials.gov/ct2/show/NCT04627467
32181795,NCT04627467,Registry,Journal Article, , ,Coronavirus Disease 2019 (COVID-19) in Italy.,2020-09-16,JAMA,https://pubmed.ncbi.nlm.nih.gov/32181795,https://clinicaltrials.gov/ct2/show/NCT04627467
32187459,NCT04353674,Registry,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Equipment and Supplies, Hospital|Health Care Rationing|Humans|Italy|Pandemics|Pneumonia, Viral|Resource Allocation|SARS-CoV-2|Triage|NA","Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line.",2020-05-18,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32187459,https://clinicaltrials.gov/ct2/show/NCT04353674
32190290,NCT04516811,Registry,Journal Article, , ,SARS-CoV-2 and COVID-19: The most important research questions.,2020-09-28,Cell &amp; bioscience,https://pubmed.ncbi.nlm.nih.gov/32190290,https://clinicaltrials.gov/ct2/show/NCT04516811
32196083,NCT04627467,Registry,Journal Article,Hydroxychloroquine|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Cytokine Release Syndrome|Disease Progression|Humans|Hydroxychloroquine|Lymphocyte Activation|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|T-Lymphocytes|NA",COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.,2020-06-24,The Journal of antimicrobial chemotherapy,https://pubmed.ncbi.nlm.nih.gov/32196083,https://clinicaltrials.gov/ct2/show/NCT04627467
32199468,NCT04627467,Registry,Letter|Comment,Antiviral Agents|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Disease Outbreaks|Feasibility Studies|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Use of antiviral drugs to reduce COVID-19 transmission.,2020-05-05,The Lancet. Global health,https://pubmed.ncbi.nlm.nih.gov/32199468,https://clinicaltrials.gov/ct2/show/NCT04627467
32205204,NCT04384380,Registry,Clinical Trial|Journal Article,Hydroxychloroquine|Azithromycin|NA,"Adult|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA",Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.,2020-08-04,International journal of antimicrobial agents,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04384380
32205204,NCT04627467,Registry,Clinical Trial|Journal Article,Hydroxychloroquine|Azithromycin|NA,"Adult|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA",Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.,2020-08-04,International journal of antimicrobial agents,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04627467
32205204,NCT04344951,Registry,Clinical Trial|Journal Article,Hydroxychloroquine|Azithromycin|NA,"Adult|Azithromycin|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Therapy, Combination|Female|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Polymerase Chain Reaction|SARS-CoV-2|Viral Load|NA",Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.,2020-08-04,International journal of antimicrobial agents,https://pubmed.ncbi.nlm.nih.gov/32205204,https://clinicaltrials.gov/ct2/show/NCT04344951
32209890,NCT04353674,Registry,Journal Article,C-Reactive Protein|Oxygen|NA,"Adult|Aged|Aged, 80 and over|Betacoronavirus|C-Reactive Protein|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Oxygen|Pandemics|Pneumonia, Viral|Retrospective Studies|SARS-CoV-2|NA","Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.",2020-06-16,Chinese medical journal,https://pubmed.ncbi.nlm.nih.gov/32209890,https://clinicaltrials.gov/ct2/show/NCT04353674
32209891,NCT04392323,Registry,Journal Article, ,"Betacoronavirus|COVID-19|Clinical Protocols|Coronavirus Infections|Elective Surgical Procedures|Epidemics|Humans|Infectious Disease Transmission, Patient-to-Professional|Pandemics|Pneumonia, Viral|SARS-CoV-2|Surgery Department, Hospital|Surgical Procedures, Operative|United States|NA",Managing COVID-19 in Surgical Systems.,2020-07-01,Annals of surgery,https://pubmed.ncbi.nlm.nih.gov/32209891,https://clinicaltrials.gov/ct2/show/NCT04392323
32213556,NCT04479202,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Betacoronavirus|COVID-19|COVID-19 Testing|China|Clinical Laboratory Techniques|Coronavirus Infections|Female|Gastrointestinal Tract|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Risk Factors|SARS-CoV-2|NA","Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.",2020-05-13,Gut,https://pubmed.ncbi.nlm.nih.gov/32213556,https://clinicaltrials.gov/ct2/show/NCT04479202
32215691,NCT04338568,Registry,Evaluation Study|Journal Article, ,"Adult|Aged|Aged, 80 and over|Area Under Curve|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|ROC Curve|Retrospective Studies|SARS-CoV-2|Thorax|Tomography, X-Ray Computed|Vision, Ocular|NA",CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19).,2020-07-14,European radiology,https://pubmed.ncbi.nlm.nih.gov/32215691,https://clinicaltrials.gov/ct2/show/NCT04338568
32219428,NCT04356482,Registry,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Glucocorticoids|Immunoglobulin G|Immunoglobulin M|Methylprednisolone|NA","Adult|Aged|Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Betacoronavirus|Blood Donors|COVID-19|Coronavirus Infections|Critical Illness|Female|Glucocorticoids|Humans|Immunization, Passive|Immunoglobulin G|Immunoglobulin M|Male|Methylprednisolone|Middle Aged|Organ Dysfunction Scores|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA",Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.,2020-09-23,JAMA,https://pubmed.ncbi.nlm.nih.gov/32219428,https://clinicaltrials.gov/ct2/show/NCT04356482
32219428,NCT04393727,Registry,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't","Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Glucocorticoids|Immunoglobulin G|Immunoglobulin M|Methylprednisolone|NA","Adult|Aged|Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|Betacoronavirus|Blood Donors|COVID-19|Coronavirus Infections|Critical Illness|Female|Glucocorticoids|Humans|Immunization, Passive|Immunoglobulin G|Immunoglobulin M|Male|Methylprednisolone|Middle Aged|Organ Dysfunction Scores|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|SARS-CoV-2|NA",Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.,2020-09-23,JAMA,https://pubmed.ncbi.nlm.nih.gov/32219428,https://clinicaltrials.gov/ct2/show/NCT04393727
32221979,NCT04424953,Registry,Comparative Study|Letter, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Laryngoscopy|Mouth|Pandemics|Pneumonia, Viral|SARS-CoV-2|Video Recording|NA",Videolaryngoscopy increases 'mouth-to-mouth' distance compared with direct laryngoscopy.,2020-06-24,Anaesthesia,https://pubmed.ncbi.nlm.nih.gov/32221979,https://clinicaltrials.gov/ct2/show/NCT04424953
32222346,NCT04501965,Registry,Journal Article|Published Erratum, , ,Corrigendum to &quot;Traditional Chinese medicine for COVID-19 treatment&quot; [Pharmacol. Res. 155 (2020) 104743].,2020-06-06,Pharmacological research,https://pubmed.ncbi.nlm.nih.gov/32222346,https://clinicaltrials.gov/ct2/show/NCT04501965
32224769,NCT04353674,Registry,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Diagnostic Techniques and Procedures|Humans|Infection Control|Intensive Care Units|Pandemics|Pneumonia, Viral|Practice Guidelines as Topic|Respiration, Artificial|SARS-CoV-2|Shock|NA",Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19).,2020-06-04,Critical care medicine,https://pubmed.ncbi.nlm.nih.gov/32224769,https://clinicaltrials.gov/ct2/show/NCT04353674
32228825,NCT04366089,Registry,Editorial,Interleukin-1|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Inflammation|Interleukin-1|Lung|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.,2020-08-10,Journal of biological regulators and homeostatic agents,https://pubmed.ncbi.nlm.nih.gov/32228825,https://clinicaltrials.gov/ct2/show/NCT04366089
32234250,NCT04392323,Registry,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't", ,"Adult|Anesthesia, Spinal|Anesthesiologists|Anesthetists|Betacoronavirus|COVID-19|China|Coronavirus Infections|Female|Humans|Male|Pandemics|Personal Protective Equipment|Pneumonia, Viral|Retrospective Studies|Risk|SARS-CoV-2|NA","Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study.",2020-05-20,British journal of anaesthesia,https://pubmed.ncbi.nlm.nih.gov/32234250,https://clinicaltrials.gov/ct2/show/NCT04392323
32250280,NCT04378738,Registry,"Journal Article|Research Support, N.I.H., Extramural", ,Adult|Aged|Cohort Studies|Communication|Cross-Sectional Studies|Female|Health Literacy|Humans|Information Seeking Behavior|Male|Middle Aged|Multilingualism|Surveys and Questionnaires|Urban Health|NA,The Use of Technology for Communicating With Clinicians or Seeking Health Information in a Multilingual Urban Cohort: Cross-Sectional Survey.,2020-11-05,Journal of medical Internet research,https://pubmed.ncbi.nlm.nih.gov/32250280,https://clinicaltrials.gov/ct2/show/NCT04378738
32250385,NCT04360837,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adolescent|Adult|Age Distribution|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|Comorbidity|Coronavirus Infections|Critical Care|Critical Illness|Female|Hospital Mortality|Hospitalization|Humans|Intensive Care Units|Italy|Male|Middle Aged|Pandemics|Pneumonia, Viral|Positive-Pressure Respiration|Respiration, Artificial|Retrospective Studies|SARS-CoV-2|Sex Distribution|Young Adult|NA","Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.",2020-09-23,JAMA,https://pubmed.ncbi.nlm.nih.gov/32250385,https://clinicaltrials.gov/ct2/show/NCT04360837
32253449,NCT04494724,Registry,Journal Article|Published Erratum, , ,"Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.",2020-09-30,Intensive care medicine,https://pubmed.ncbi.nlm.nih.gov/32253449,https://clinicaltrials.gov/ct2/show/NCT04494724
32257537,NCT04517162,Registry,Journal Article, , ,Transplantation of ACE2<sup>-</sup> Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.,2020-09-28,Aging and disease,https://pubmed.ncbi.nlm.nih.gov/32257537,https://clinicaltrials.gov/ct2/show/NCT04517162
32257537,NCT04361942,Registry,Journal Article, , ,Transplantation of ACE2<sup>-</sup> Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.,2020-09-28,Aging and disease,https://pubmed.ncbi.nlm.nih.gov/32257537,https://clinicaltrials.gov/ct2/show/NCT04361942
32259322,NCT04392323,Registry,Journal Article, ,"Adult|Betacoronavirus|COVID-19|China|Coronavirus Infections|Female|Genital Neoplasms, Female|Gynecologic Surgical Procedures|Hospitalization|Humans|Incidence|Male|Mass Screening|Medical Records|Middle Aged|Pandemics|Pneumonia, Viral|Postoperative Complications|Retrospective Studies|SARS-CoV-2|NA",Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records.,2020-06-23,The oncologist,https://pubmed.ncbi.nlm.nih.gov/32259322,https://clinicaltrials.gov/ct2/show/NCT04392323
32259546,NCT04392323,Registry,Case Reports|Journal Article, ,"Betacoronavirus|COVID-19|Contact Tracing|Coronavirus Infections|Cross Infection|Disease Transmission, Infectious|Female|Hong Kong|Hospitals|Humans|Infection Control|Middle Aged|Pandemics|Patients' Rooms|Pneumonia, Viral|SARS-CoV-2|NA",Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong.,2020-06-16,The Journal of hospital infection,https://pubmed.ncbi.nlm.nih.gov/32259546,https://clinicaltrials.gov/ct2/show/NCT04392323
32282022,NCT04480593,Registry,Journal Article|Review,Adrenal Cortex Hormones|Amides|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Antiviral Agents|Immunoglobulins|Immunologic Factors|Indoles|Pyrazines|Oseltamivir|Lopinavir|remdesivir|Adenosine Monophosphate|Ribavirin|Hydroxychloroquine|Azithromycin|Chloroquine|umifenovir|favipiravir|Ritonavir|Alanine|NA,"Adenosine Monophosphate|Adrenal Cortex Hormones|Alanine|Amides|Angiotensin Receptor Antagonists|Angiotensin-Converting Enzyme Inhibitors|Antiviral Agents|Azithromycin|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Humans|Hydroxychloroquine|Immunoglobulins|Immunologic Factors|Indoles|Lopinavir|Oseltamivir|Pandemics|Pneumonia, Viral|Pyrazines|Ribavirin|Ritonavir|SARS-CoV-2|Withholding Treatment|NA",Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.,2020-09-23,JAMA,https://pubmed.ncbi.nlm.nih.gov/32282022,https://clinicaltrials.gov/ct2/show/NCT04480593
32292899,NCT04392323,Registry,Journal Article, , ,Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.,2021-02-09,EClinicalMedicine,https://pubmed.ncbi.nlm.nih.gov/32292899,https://clinicaltrials.gov/ct2/show/NCT04392323
32293834,NCT04392713,Registry,Journal Article|Review,Amides|Antiviral Agents|Drug Combinations|Pyrazines|Thiazoles|lopinavir-ritonavir drug combination|Lopinavir|remdesivir|Adenosine Monophosphate|Hydroxychloroquine|Ivermectin|Chloroquine|favipiravir|Ritonavir|Alanine|nitazoxanide|NA,"Adenosine Monophosphate|Alanine|Amides|Antiviral Agents|Betacoronavirus|COVID-19|Chloroquine|Coronavirus Infections|Drug Combinations|Humans|Hydroxychloroquine|Ivermectin|Lopinavir|Pandemics|Pneumonia, Viral|Pyrazines|Ritonavir|SARS-CoV-2|Thiazoles|NA",Antiviral treatment of COVID-19,2020-04-22,Turkish journal of medical sciences,https://pubmed.ncbi.nlm.nih.gov/32293834,https://clinicaltrials.gov/ct2/show/NCT04392713
32298251,NCT04530617,Registry,Published Erratum, , ,"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.",2021-01-11,MMWR. Morbidity and mortality weekly report,https://pubmed.ncbi.nlm.nih.gov/32298251,https://clinicaltrials.gov/ct2/show/NCT04530617
32302438,NCT04466670,Registry,Journal Article,Biomarkers|Inflammation Mediators|NA,"Adult|Aged|Betacoronavirus|Biomarkers|Blood Coagulation|COVID-19|Case-Control Studies|Coronavirus Infections|Host-Pathogen Interactions|Humans|Inflammation Mediators|Intensive Care Units|Middle Aged|Pandemics|Pneumonia, Viral|Predictive Value of Tests|SARS-CoV-2|Thrombelastography|Thrombophilia|Young Adult|NA",Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis.,2020-07-15,Journal of thrombosis and haemostasis : JTH,https://pubmed.ncbi.nlm.nih.gov/32302438,https://clinicaltrials.gov/ct2/show/NCT04466670
32302462,NCT04466670,Registry,Letter|Comment, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment.,2020-08-06,Journal of thrombosis and haemostasis : JTH,https://pubmed.ncbi.nlm.nih.gov/32302462,https://clinicaltrials.gov/ct2/show/NCT04466670
32303365,NCT04366089,Registry,Journal Article,Antioxidants|Ascorbic Acid|NA,"Antioxidants|Ascorbic Acid|Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.,2020-05-21,Revista espanola de anestesiologia y reanimacion,https://pubmed.ncbi.nlm.nih.gov/32303365,https://clinicaltrials.gov/ct2/show/NCT04366089
32312790,NCT04479202,Registry,Letter,Biomarkers|Leukocyte L1 Antigen Complex|NA,"Adult|Aged|Aged, 80 and over|Betacoronavirus|Biomarkers|COVID-19|Coronavirus Infections|Feces|Female|Humans|Inflammatory Bowel Diseases|Leukocyte L1 Antigen Complex|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Faecal calprotectin indicates intestinal inflammation in COVID-19.,2020-07-16,Gut,https://pubmed.ncbi.nlm.nih.gov/32312790,https://clinicaltrials.gov/ct2/show/NCT04479202
32313880,NCT04480593,Registry,Journal Article|Review, , ,PAK1-blockers: Potential Therapeutics against COVID-19.,2021-01-10,Medicine in drug discovery,https://pubmed.ncbi.nlm.nih.gov/32313880,https://clinicaltrials.gov/ct2/show/NCT04480593
32314249,NCT04392323,Registry,Journal Article,Anti-Retroviral Agents|Immunosuppressive Agents|Hydroxychloroquine|NA,"Adult|Anti-Retroviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Cough|Dyspnea|Fatigue|Female|Fever|Gastric Bypass|Humans|Hydroxychloroquine|Immunosuppressive Agents|Iran|Male|Middle Aged|Off-Label Use|Pandemics|Patient Readmission|Pneumonia, Viral|Postoperative Complications|SARS-CoV-2|NA",Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak.,2020-08-10,Obesity surgery,https://pubmed.ncbi.nlm.nih.gov/32314249,https://clinicaltrials.gov/ct2/show/NCT04392323
32315809,NCT04568356,Registry,Comparative Study|Journal Article, ,"Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|China|Clinical Laboratory Techniques|Coronavirus Infections|Diagnostic Tests, Routine|Female|Humans|Male|Middle Aged|Nasopharynx|Pandemics|Pneumonia, Viral|SARS-CoV-2|Young Adult|NA",Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously.,2020-05-20,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,https://pubmed.ncbi.nlm.nih.gov/32315809,https://clinicaltrials.gov/ct2/show/NCT04568356
32320517,NCT04466670,Registry,Journal Article|Multicenter Study,Anticoagulants|NA,"Aged|Anticoagulants|Betacoronavirus|Blood Coagulation|COVID-19|Coronavirus Infections|Female|France|Host-Parasite Interactions|Humans|Incidence|Male|Middle Aged|Pandemics|Pneumonia, Viral|Pulmonary Embolism|Retrospective Studies|Risk Factors|SARS-CoV-2|Severity of Illness Index|Treatment Outcome|Venous Thromboembolism|Venous Thrombosis|NA",High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients.,2020-07-15,Journal of thrombosis and haemostasis : JTH,https://pubmed.ncbi.nlm.nih.gov/32320517,https://clinicaltrials.gov/ct2/show/NCT04466670
32322397,NCT04673214,Registry,Journal Article|Review, , ,"Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.",2021-01-10,New microbes and new infections,https://pubmed.ncbi.nlm.nih.gov/32322397,https://clinicaltrials.gov/ct2/show/NCT04673214
32329246,NCT04466670,Registry,Journal Article|Review,Fibrinolytic Agents|Tissue Plasminogen Activator|NA,"Betacoronavirus|COVID-19|Coronavirus Infections|Drug Repositioning|Fibrinolysis|Fibrinolytic Agents|Host-Pathogen Interactions|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombolytic Therapy|Tissue Plasminogen Activator|Treatment Outcome|NA",Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.,2020-07-15,Journal of thrombosis and haemostasis : JTH,https://pubmed.ncbi.nlm.nih.gov/32329246,https://clinicaltrials.gov/ct2/show/NCT04466670
32342871,NCT04394182,Registry,Editorial|Comment, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?,2020-06-25,Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,https://pubmed.ncbi.nlm.nih.gov/32342871,https://clinicaltrials.gov/ct2/show/NCT04394182
32356900,NCT04424953,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adult|Airway Management|Australia|Betacoronavirus|COVID-19|Consensus|Coronavirus Infections|Female|Humans|Infection Control|Intubation, Intratracheal|Male|New Zealand|Pandemics|Pneumonia, Viral|Practice Guidelines as Topic|SARS-CoV-2|NA",Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group.,2020-06-12,The Medical journal of Australia,https://pubmed.ncbi.nlm.nih.gov/32356900,https://clinicaltrials.gov/ct2/show/NCT04424953
32356910,NCT04488484,Registry,Journal Article|Systematic Review,"Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|NA","Antibodies, Neutralizing|Antibodies, Viral|Antiviral Agents|COVID-19|Humans|Immunization, Passive|NA",Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.,2020-12-16,Journal of medical virology,https://pubmed.ncbi.nlm.nih.gov/32356910,https://clinicaltrials.gov/ct2/show/NCT04488484
32360300,NCT04480593,Registry,Journal Article|Review,Phytochemicals|NA,"Animals|Betacoronavirus|COVID-19|Coronavirus Infections|Coronavirus, Feline|Humans|Infectious bronchitis virus|Middle East Respiratory Syndrome Coronavirus|Pandemics|Phytochemicals|Pneumonia, Viral|Porcine epidemic diarrhea virus|SARS Virus|SARS-CoV-2|NA",Natural product-derived phytochemicals as potential agents against coronaviruses: A review.,2020-06-02,Virus research,https://pubmed.ncbi.nlm.nih.gov/32360300,https://clinicaltrials.gov/ct2/show/NCT04480593
32369666,NCT04466670,Registry,Comparative Study|Journal Article,Anticoagulants|Biomarkers|Fibrin Fibrinogen Degradation Products|fibrin fragment D|NA,"Aged|Anticoagulants|Betacoronavirus|Biomarkers|COVID-19|Catheterization, Central Venous|Coronavirus Infections|Female|Fibrin Fibrinogen Degradation Products|Humans|Incidence|Intensive Care Units|Male|Middle Aged|Netherlands|Pandemics|Patients' Rooms|Pneumonia, Viral|Pulmonary Embolism|Retrospective Studies|Risk Factors|SARS-CoV-2|Thrombophilia|Thrombophlebitis|Venous Thromboembolism|Venous Thrombosis|NA",Incidence of venous thromboembolism in hospitalized patients with COVID-19.,2020-08-14,Journal of thrombosis and haemostasis : JTH,https://pubmed.ncbi.nlm.nih.gov/32369666,https://clinicaltrials.gov/ct2/show/NCT04466670
32373721,NCT04394182,Registry,Journal Article, , ,Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.,2020-09-28,Clinical and translational radiation oncology,https://pubmed.ncbi.nlm.nih.gov/32373721,https://clinicaltrials.gov/ct2/show/NCT04394182
32381426,NCT04392323,Registry,Journal Article, ,"Adult|Aged|COVID-19|Coronavirus Infections|Cross Infection|Digestive System Surgical Procedures|Female|Hospital Departments|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Retrospective Studies|NA",Nosocomial infection with SARS-Cov-2Â within Departments of Digestive Surgery.,2020-07-06,Journal of visceral surgery,https://pubmed.ncbi.nlm.nih.gov/32381426,https://clinicaltrials.gov/ct2/show/NCT04392323
32387623,NCT04466670,Registry,Letter,Anticoagulants|NA,"Anticoagulants|Betacoronavirus|COVID-19|Cardiovascular Diseases|Comorbidity|Coronavirus Infections|Hemorrhage|Hospitalization|Humans|Length of Stay|Mortality|New York City|Outcome and Process Assessment, Health Care|Pandemics|Pneumonia, Viral|Respiration, Artificial|Risk Assessment|SARS-CoV-2|NA",Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.,2020-07-13,Journal of the American College of Cardiology,https://pubmed.ncbi.nlm.nih.gov/32387623,https://clinicaltrials.gov/ct2/show/NCT04466670
32395391,NCT04568356,Registry,Journal Article, , ,Development of a rapid test kit for SARS-CoV-2: an example of product design.,2020-09-28,Bio-design and manufacturing,https://pubmed.ncbi.nlm.nih.gov/32395391,https://clinicaltrials.gov/ct2/show/NCT04568356
32396163,NCT04517162,Registry,"Journal Article|Research Support, Non-U.S. Gov't|Validation Study", ,"Adult|Aged|Betacoronavirus|COVID-19|COVID-19 Testing|China|Clinical Laboratory Techniques|Cohort Studies|Coronavirus Infections|Critical Care|Critical Illness|Female|Hospitalization|Humans|Male|Middle Aged|Pandemics|Pneumonia, Viral|Risk Assessment|SARS-CoV-2|NA",Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19.,2020-10-02,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/32396163,https://clinicaltrials.gov/ct2/show/NCT04517162
32401873,NCT04522492,Registry,Journal Article|Randomized Controlled Trial, ,Anxiety Disorders|Cognitive Behavioral Therapy|Comorbidity|Humans|Trichotillomania|NA,Skin picking treatment with the Rothbaum cognitive behavioral therapy protocol: a randomized clinical trial.,2020-11-09,"Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)",https://pubmed.ncbi.nlm.nih.gov/32401873,https://clinicaltrials.gov/ct2/show/NCT04522492
32404476,NCT04488484,Registry,"Journal Article|Research Support, Non-U.S. Gov't", ,"Adolescent|Adult|Aged|Aged, 80 and over|COVID-19|Coronavirus Infections|Cost of Illness|Critical Care|Female|France|Hospitalization|Humans|Immunity|Male|Middle Aged|Pandemics|Pneumonia, Viral|Quarantine|SARS Virus|Young Adult|NA",Estimating the burden of SARS-CoV-2 in France.,2020-07-16,"Science (New York, N.Y.)",https://pubmed.ncbi.nlm.nih.gov/32404476,https://clinicaltrials.gov/ct2/show/NCT04488484
32404480,NCT04568356,Registry,Evaluation Study|Letter,"Antigens, Viral|NA","Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Immunoassay|Nasopharynx|Pandemics|Pneumonia, Viral|Point-of-Care Testing|SARS-CoV-2|Sensitivity and Specificity|NA",Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs.,2020-08-04,Journal of clinical microbiology,https://pubmed.ncbi.nlm.nih.gov/32404480,https://clinicaltrials.gov/ct2/show/NCT04568356
32419926,NCT04382768,Registry,Journal Article,"COVID-19 Vaccines|Receptors, Virus|Spike Glycoprotein, Coronavirus|spike protein, SARS-CoV-2|ACE2 protein, human|Angiotensin-Converting Enzyme 2|NA","Angiotensin-Converting Enzyme 2|COVID-19|COVID-19 Vaccines|China|Humans|Receptors, Virus|SARS-CoV-2|Spike Glycoprotein, Coronavirus|Viral Tropism|NA","Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.",2021-01-21,F1000Research,https://pubmed.ncbi.nlm.nih.gov/32419926,https://clinicaltrials.gov/ct2/show/NCT04382768
32422057,NCT04568356,Registry,"Journal Article|Research Support, N.I.H., Extramural|Research Support, N.I.H., Intramural|Review", ,"Bayes Theorem|Betacoronavirus|COVID-19|Coronavirus Infections|False Negative Reactions|Humans|Pandemics|Pneumonia, Viral|Reproducibility of Results|Reverse Transcriptase Polymerase Chain Reaction|Risk Factors|SARS-CoV-2|NA",Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.,2020-08-27,Annals of internal medicine,https://pubmed.ncbi.nlm.nih.gov/32422057,https://clinicaltrials.gov/ct2/show/NCT04568356
32437596,NCT04466670,Registry,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't", ,"Aged|Aged, 80 and over|Autopsy|Betacoronavirus|COVID-19|Coronavirus Infections|Endothelium, Vascular|Female|Humans|Influenza A Virus, H1N1 Subtype|Influenza, Human|Lung|Male|Middle Aged|Neovascularization, Pathologic|Pandemics|Pneumonia, Viral|Respiratory Distress Syndrome|Respiratory Insufficiency|SARS-CoV-2|Thrombosis|NA","Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.",2020-07-16,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32437596,https://clinicaltrials.gov/ct2/show/NCT04466670
32445064,NCT04466670,Registry,Journal Article,Anticoagulants|Heparin|NA,"Adult|Aged|Anticoagulants|Betacoronavirus|Blood Coagulation|Blood Coagulation Tests|COVID-19|Coronavirus Infections|Drug Monitoring|Drug Resistance|Female|Heparin|Host-Pathogen Interactions|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Pneumonia, Viral|Retrospective Studies|SARS-CoV-2|Thrombosis|Treatment Outcome|NA",Heparin resistance in COVID-19 patients in the intensive care unit.,2020-07-22,Journal of thrombosis and thrombolysis,https://pubmed.ncbi.nlm.nih.gov/32445064,https://clinicaltrials.gov/ct2/show/NCT04466670
32445440,NCT04647695,Registry,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Adult|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Double-Blind Method|Extracorporeal Membrane Oxygenation|Female|Humans|Kaplan-Meier Estimate|Male|Middle Aged|Oxygen Inhalation Therapy|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Time Factors|Young Adult|NA",Remdesivir for the Treatment of Covid-19 - Final Report.,2020-12-01,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32445440,https://clinicaltrials.gov/ct2/show/NCT04647695
32450344,NCT04466670,Registry,"Clinical Trial, Phase II|Controlled Clinical Trial|Journal Article",Fibrin Fibrinogen Degradation Products|Platelet Aggregation Inhibitors|fibrin fragment D|Clopidogrel|Tirofiban|Aspirin|NA,"Aged|Aspirin|Betacoronavirus|COVID-19|Clopidogrel|Compassionate Use Trials|Coronavirus Infections|Female|Fibrin Fibrinogen Degradation Products|Humans|Hypoxia|Male|Middle Aged|Pandemics|Platelet Aggregation Inhibitors|Pneumonia, Viral|Proof of Concept Study|SARS-CoV-2|Thrombophilia|Tirofiban|NA","Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.",2020-07-20,Pharmacological research,https://pubmed.ncbi.nlm.nih.gov/32450344,https://clinicaltrials.gov/ct2/show/NCT04466670
32459672,NCT04466670,Registry,Journal Article|Observational Study,Anticoagulants|Biomarkers|NA,"Adolescent|Adult|Aged|Aged, 80 and over|Anticoagulants|Betacoronavirus|Biomarkers|COVID-19|Comorbidity|Coronavirus Infections|Critical Illness|Female|Humans|Intensive Care Units|Male|Middle Aged|Pandemics|Pneumonia, Viral|SARS-CoV-2|Thrombelastography|Thrombophilia|Venous Thromboembolism|Young Adult|NA",Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019.,2020-09-02,Critical care medicine,https://pubmed.ncbi.nlm.nih.gov/32459672,https://clinicaltrials.gov/ct2/show/NCT04466670
32461699,NCT04454606,Registry,Journal Article|Published Erratum, , ,Author Correction: Respiratory virus shedding in exhaled breath and efficacy of face masks.,2020-10-21,Nature medicine,https://pubmed.ncbi.nlm.nih.gov/32461699,https://clinicaltrials.gov/ct2/show/NCT04454606
32462179,NCT04466670,Registry,Letter,Anticoagulants|Platelet Aggregation Inhibitors|Protective Agents|NA,"Adult|Aged|Anticoagulants|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Humans|Male|Middle Aged|Pandemics|Platelet Aggregation Inhibitors|Pneumonia, Viral|Propensity Score|Protective Agents|Protective Factors|Retrospective Studies|SARS-CoV-2|Survival Analysis|NA",Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.,2020-07-14,Blood,https://pubmed.ncbi.nlm.nih.gov/32462179,https://clinicaltrials.gov/ct2/show/NCT04466670
32485618,NCT04568356,Registry,Journal Article,"Antigens, Viral|NA","Adolescent|Adult|Aged|Aged, 80 and over|Animals|Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Child|Child, Preschool|Clinical Laboratory Techniques|Coronavirus Infections|Female|Humans|Immunoassay|Infant|Infant, Newborn|Male|Middle Aged|Nasopharynx|Pandemics|Pneumonia, Viral|SARS-CoV-2|Sensitivity and Specificity|Young Adult|NA",Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.,2020-08-11,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,https://pubmed.ncbi.nlm.nih.gov/32485618,https://clinicaltrials.gov/ct2/show/NCT04568356
32492293,NCT04308668,Registry,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't",Hydroxychloroquine|NA,"Adult|Betacoronavirus|COVID-19|Canada|Coronavirus Infections|Double-Blind Method|Female|Humans|Hydroxychloroquine|Inhalation Exposure|Male|Middle Aged|Occupational Exposure|Pandemics|Pneumonia, Viral|Post-Exposure Prophylaxis|SARS-CoV-2|Treatment Failure|United States|NA",A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,2020-08-12,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32492293,https://clinicaltrials.gov/ct2/show/NCT04308668
32497809,NCT04568356,Registry,Evaluation Study|Journal Article, ,"Adolescent|Adult|Aged|Aged, 80 and over|Betacoronavirus|COVID-19|COVID-19 Testing|COVID-19 Vaccines|Child|Child, Preschool|Clinical Laboratory Techniques|Coronavirus Infections|Female|Humans|Infant|Male|Middle Aged|Nasopharynx|Pandemics|Pneumonia, Viral|SARS-CoV-2|Sensitivity and Specificity|Viral Load|Young Adult|NA",Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.,2020-11-02,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,https://pubmed.ncbi.nlm.nih.gov/32497809,https://clinicaltrials.gov/ct2/show/NCT04568356
32504944,NCT04568356,Registry,Journal Article|Comment, , ,Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital.,2020-08-04,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,https://pubmed.ncbi.nlm.nih.gov/32504944,https://clinicaltrials.gov/ct2/show/NCT04568356
32541583,NCT04627467,Registry,Historical Article|Journal Article|Review, ,"COVID-19|China|Coronavirus Infections|Health Personnel|History, 21st Century|Humans|Infectious Disease Transmission, Patient-to-Professional|Pandemics|Pneumonia, Viral|NA","To Protect Health Care Workers Better, To Save More Lives With COVID-19.",2020-06-25,Anesthesia and analgesia,https://pubmed.ncbi.nlm.nih.gov/32541583,https://clinicaltrials.gov/ct2/show/NCT04627467
32542934,NCT04568356,Registry,"Journal Article|Research Support, Non-U.S. Gov't|Review", ,"Adult|COVID-19|COVID-19 Testing|Diagnostic Tests, Routine|Emergency Service, Hospital|Female|Humans|Pandemics|Physical Examination|SARS-CoV-2|Tomography, X-Ray Computed|NA","Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases.",2020-12-21,Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,https://pubmed.ncbi.nlm.nih.gov/32542934,https://clinicaltrials.gov/ct2/show/NCT04568356
32577640,NCT04568356,Registry,Preprint, , ,SARS-CoV2 Testing: The Limit of Detection Matters.,2020-09-28,bioRxiv : the preprint server for biology,https://pubmed.ncbi.nlm.nih.gov/32577640,https://clinicaltrials.gov/ct2/show/NCT04568356
32585619,NCT04568356,Registry,Evaluation Study|Journal Article,"Antigens, Viral|NA","Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Immunoassay|Pandemics|Pneumonia, Viral|SARS-CoV-2|Sensitivity and Specificity|NA",Evaluation of rapid antigen test for detection of SARS-CoV-2 virus.,2020-08-11,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,https://pubmed.ncbi.nlm.nih.gov/32585619,https://clinicaltrials.gov/ct2/show/NCT04568356
32595361,NCT04517422,Registry,Journal Article, , ,Gut-lung axis and dysbiosis in COVID-19.,2020-09-28,Turkish journal of biology = Turk biyoloji dergisi,https://pubmed.ncbi.nlm.nih.gov/32595361,https://clinicaltrials.gov/ct2/show/NCT04517422
32636214,NCT04568356,Registry,"Journal Article|Research Support, Non-U.S. Gov't","Antigens, Viral|RNA, Viral|NA","Adolescent|Adult|Aged|Aged, 80 and over|Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Female|Humans|Immunoassay|Male|Middle Aged|Nucleic Acid Amplification Techniques|Pandemics|Pneumonia, Viral|RNA, Viral|SARS-CoV-2|Saliva|Sensitivity and Specificity|Specimen Handling|Young Adult|NA","Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19.",2020-09-08,Journal of clinical microbiology,https://pubmed.ncbi.nlm.nih.gov/32636214,https://clinicaltrials.gov/ct2/show/NCT04568356
32645713,NCT04517422,Registry,Journal Article, , ,"Microbiota and Covid-19. Which came first, the chicken or the egg?",2020-09-01,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,https://pubmed.ncbi.nlm.nih.gov/32645713,https://clinicaltrials.gov/ct2/show/NCT04517422
32646750,NCT04568356,Registry,Journal Article,"RNA, Viral|NA","Adult|Betacoronavirus|COVID-19|COVID-19 Testing|Child|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Nasopharynx|Pandemics|Pneumonia, Viral|RNA, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|NA",How to perform a nasopharyngeal swab in adults and children in the COVID-19 era.,2020-09-10,"European annals of otorhinolaryngology, head and neck diseases",https://pubmed.ncbi.nlm.nih.gov/32646750,https://clinicaltrials.gov/ct2/show/NCT04568356
32670091,NCT04517422,Registry,Journal Article|Review, , ,The Modulation of Mucosal Antiviral Immunity by Immunobiotics: Could They Offer Any Benefit in the SARS-CoV-2 Pandemic?,2020-09-28,Frontiers in physiology,https://pubmed.ncbi.nlm.nih.gov/32670091,https://clinicaltrials.gov/ct2/show/NCT04517422
32678530,NCT04381936,Registry,Journal Article, , ,Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.,2021-02-17,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/32678530,https://clinicaltrials.gov/ct2/show/NCT04381936
32692185,NCT04685512,Registry,"Journal Article|Research Support, N.I.H., Extramural",Antiviral Agents|Dideoxynucleosides|Viral Nonstructural Proteins|RNA-Dependent RNA Polymerase|Sofosbuvir|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Dideoxynucleosides|Humans|Pandemics|Pneumonia, Viral|RNA-Dependent RNA Polymerase|SARS-CoV-2|Sofosbuvir|Viral Nonstructural Proteins|NA","Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.",2020-11-30,Journal of proteome research,https://pubmed.ncbi.nlm.nih.gov/32692185,https://clinicaltrials.gov/ct2/show/NCT04685512
32723665,NCT04514705,Registry,Editorial, ,COVID-19|Humans|Recovery of Function|Respiratory Therapy|SARS-CoV-2|NA,Recovery after COVID-19: The potential role of pulmonary rehabilitation.,2021-01-13,Brazilian journal of physical therapy,https://pubmed.ncbi.nlm.nih.gov/32723665,https://clinicaltrials.gov/ct2/show/NCT04514705
32728349,NCT04517422,Registry,Journal Article, , ,Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients.,2020-09-28,Biological procedures online,https://pubmed.ncbi.nlm.nih.gov/32728349,https://clinicaltrials.gov/ct2/show/NCT04517422
32732744,NCT04514705,Registry,Case Reports|Journal Article, ,"Aged|Betacoronavirus|COVID-19|Coronavirus Infections|Drainage, Postural|Exercise Therapy|Humans|Japan|Male|Pandemics|Pneumonia, Viral|Respiration, Artificial|Respiratory Therapy|SARS-CoV-2|Treatment Outcome|NA",Rehabilitation Therapy for a COVID-19 Patient Who Received Mechanical Ventilation in Japan.,2020-09-29,American journal of physical medicine &amp; rehabilitation,https://pubmed.ncbi.nlm.nih.gov/32732744,https://clinicaltrials.gov/ct2/show/NCT04514705
32733907,NCT04517422,Registry,Journal Article, , ,Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.,2020-09-28,Frontiers in medicine,https://pubmed.ncbi.nlm.nih.gov/32733907,https://clinicaltrials.gov/ct2/show/NCT04517422
32737507,NCT04514705,Registry,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review", ,"Betacoronavirus|COVID-19|Coronavirus Infections|Exercise|Health Status|Humans|Pandemics|Pneumonia, Viral|Recovery of Function|SARS-CoV-2|NA",Systematic Review of Changes and Recovery in Physical Function and Fitness After Severe Acute Respiratory Syndrome-Related Coronavirus Infection: Implications for COVID-19 Rehabilitation.,2020-10-07,Physical therapy,https://pubmed.ncbi.nlm.nih.gov/32737507,https://clinicaltrials.gov/ct2/show/NCT04514705
32745548,NCT04578158,Registry,Journal Article,Antiviral Agents|Protease Inhibitors|Viral Nonstructural Proteins|Quercetin|Cysteine Endopeptidases|Coronavirus 3C Proteases|NA,"Antiviral Agents|Betacoronavirus|COVID-19|Catalytic Domain|Coronavirus 3C Proteases|Coronavirus Infections|Cysteine Endopeptidases|Drug Discovery|Humans|Molecular Docking Simulation|Pandemics|Pneumonia, Viral|Protease Inhibitors|Protein Conformation|Protein Unfolding|Quercetin|SARS-CoV-2|Viral Nonstructural Proteins|NA",Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.,2020-11-23,International journal of biological macromolecules,https://pubmed.ncbi.nlm.nih.gov/32745548,https://clinicaltrials.gov/ct2/show/NCT04578158
32759457,NCT04514705,Registry,Journal Article, ,"Betacoronavirus|COVID-19|Coronavirus Infections|Critical Illness|England|Humans|Pandemics|Pneumonia, Viral|SARS-CoV-2|NA",An interdisciplinary approach to the management of critically ill patients during covid-19 pandemic; an experience of a university hospital in England.,2020-08-11,"Wiadomosci lekarskie (Warsaw, Poland : 1960)",https://pubmed.ncbi.nlm.nih.gov/32759457,https://clinicaltrials.gov/ct2/show/NCT04514705
32766458,NCT04514705,Registry,Journal Article, , ,Occupational therapy: The key to unlocking locked-up occupations during the COVID-19 pandemic.,2020-09-28,Wellcome open research,https://pubmed.ncbi.nlm.nih.gov/32766458,https://clinicaltrials.gov/ct2/show/NCT04514705
32780788,NCT04517422,Registry,Journal Article, , ,Gut microbiota and COVID-19: A superfluous diagnostic biomarker or therapeutic target?,2020-09-01,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,https://pubmed.ncbi.nlm.nih.gov/32780788,https://clinicaltrials.gov/ct2/show/NCT04517422
32800855,NCT04568356,Registry,Comparative Study|Journal Article|Validation Study, ,"Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|Humans|Immunoenzyme Techniques|Luminescent Measurements|Nasal Cavity|Pandemics|Pneumonia, Viral|Real-Time Polymerase Chain Reaction|SARS-CoV-2|Sensitivity and Specificity|Viral Load|NA","Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients.",2020-10-28,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,https://pubmed.ncbi.nlm.nih.gov/32800855,https://clinicaltrials.gov/ct2/show/NCT04568356
32821939,NCT04292730,Registry,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't",Antiviral Agents|remdesivir|Adenosine Monophosphate|Alanine|NA,"Adenosine Monophosphate|Administration, Intravenous|Aged|Alanine|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Drug Administration Schedule|Female|Hospitalization|Humans|Male|Middle Aged|Odds Ratio|Pandemics|Patient Acuity|Pneumonia, Viral|SARS-CoV-2|Treatment Outcome|NA",Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.,2020-09-29,JAMA,https://pubmed.ncbi.nlm.nih.gov/32821939,https://clinicaltrials.gov/ct2/show/NCT04292730
32823866,NCT04568356,Registry,Journal Article, , ,Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2.,2020-09-28,"Diagnostics (Basel, Switzerland)",https://pubmed.ncbi.nlm.nih.gov/32823866,https://clinicaltrials.gov/ct2/show/NCT04568356
32845525,NCT04568356,Registry,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review","Antigens, Viral|NA","Antigens, Viral|Betacoronavirus|COVID-19|COVID-19 Testing|Clinical Laboratory Techniques|Coronavirus Infections|False Negative Reactions|False Positive Reactions|Humans|Pandemics|Pneumonia, Viral|Point-of-Care Systems|SARS-CoV-2|Sensitivity and Specificity|NA","Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.",2020-09-16,The Cochrane database of systematic reviews,https://pubmed.ncbi.nlm.nih.gov/32845525,https://clinicaltrials.gov/ct2/show/NCT04568356
32883593,NCT04343261,Registry,"Clinical Trial, Phase II|Journal Article","Antibodies, Viral|Immunoglobulin G|Immunoglobulin M|NA","Adult|Aged|Antibodies, Viral|COVID-19|Female|Humans|Immunization, Passive|Immunoglobulin G|Immunoglobulin M|Male|Middle Aged|SARS-CoV-2|NA",SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma.,2020-12-21,Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,https://pubmed.ncbi.nlm.nih.gov/32883593,https://clinicaltrials.gov/ct2/show/NCT04343261
32951151,NCT04343261,Registry,Journal Article, , ,Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective PhaseÂ II Clinical Trial.,2021-01-29,Infectious diseases and therapy,https://pubmed.ncbi.nlm.nih.gov/32951151,https://clinicaltrials.gov/ct2/show/NCT04343261
32960881,NCT04568356,Registry,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review", ,"Asymptomatic Diseases|Asymptomatic Infections|Betacoronavirus|COVID-19|Coronavirus Infections|Disease Progression|Humans|Mass Screening|Pandemics|Pneumonia, Viral|Reverse Transcriptase Polymerase Chain Reaction|SARS-CoV-2|NA",Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.,2020-10-01,PLoS medicine,https://pubmed.ncbi.nlm.nih.gov/32960881,https://clinicaltrials.gov/ct2/show/NCT04568356
32992075,NCT04486508,Registry,Clinical Trial Protocol|Journal Article,Anticoagulants|Enoxaparin|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Atorvastatin|NA,Anticoagulants|Atorvastatin|COVID-19|Critical Illness|Double-Blind Method|Enoxaparin|Humans|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Iran|Multicenter Studies as Topic|Randomized Controlled Trials as Topic|Thrombosis|Time Factors|Treatment Outcome|Venous Thromboembolism|NA,Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.,2020-12-10,Thrombosis research,https://pubmed.ncbi.nlm.nih.gov/32992075,https://clinicaltrials.gov/ct2/show/NCT04486508
33001138,NCT04329923,Registry,Journal Article|Multicenter Study|Randomized Controlled Trial,Hydroxychloroquine|NA,"Adult|COVID-19|Cross Infection|Double-Blind Method|Female|Hospitals, Urban|Humans|Hydroxychloroquine|Incidence|Male|Pennsylvania|Personnel, Hospital|Pre-Exposure Prophylaxis|SARS-CoV-2|NA",Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.,2021-02-05,JAMA internal medicine,https://pubmed.ncbi.nlm.nih.gov/33001138,https://clinicaltrials.gov/ct2/show/NCT04329923
33031652,NCT04381936,Registry,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial,Antiviral Agents|Hydroxychloroquine|NA,"Aged|Aged, 80 and over|Antiviral Agents|Betacoronavirus|COVID-19|Coronavirus Infections|Female|Hospitalization|Humans|Hydroxychloroquine|Male|Middle Aged|Pandemics|Pneumonia, Viral|Respiration, Artificial|SARS-CoV-2|Treatment Failure|NA",Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.,2020-12-01,The New England journal of medicine,https://pubmed.ncbi.nlm.nih.gov/33031652,https://clinicaltrials.gov/ct2/show/NCT04381936
33179911,NCT04578158,Registry,Journal Article,"Angiotensin-Converting Enzyme Inhibitors|Polyphenols|Recombinant Proteins|Quercetin|Peptidyl-Dipeptidase A|ACE2 protein, human|Angiotensin-Converting Enzyme 2|NA",Angiotensin-Converting Enzyme 2|Angiotensin-Converting Enzyme Inhibitors|Enzyme Assays|Humans|Kinetics|Peptidyl-Dipeptidase A|Polyphenols|Quercetin|Recombinant Proteins|Temperature|NA,Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity.,2020-12-01,Journal of agricultural and food chemistry,https://pubmed.ncbi.nlm.nih.gov/33179911,https://clinicaltrials.gov/ct2/show/NCT04578158
33215159,NCT04721457,Registry,Journal Article, , ,Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection.,2021-02-11,"Function (Oxford, England)",https://pubmed.ncbi.nlm.nih.gov/33215159,https://clinicaltrials.gov/ct2/show/NCT04721457
33390932,NCT04705753,Registry,Journal Article|Review, , ,"The Therapeutic Potential of the Essential Oil of <i>Thymbra capitata</i> (L.) Cav., <i>Origanum dictamnus</i> L. and <i>Salvia fruticosa</i> Mill. And a Case of Plant-Based Pharmaceutical Development.",2021-01-05,Frontiers in pharmacology,https://pubmed.ncbi.nlm.nih.gov/33390932,https://clinicaltrials.gov/ct2/show/NCT04705753
